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CHAPTER 1: GENERAL INTRODUCTION
1.1 Pyrimidine Biosynthesis
Pyrimidines play a significant role in a variety of life processes. They are the
building blocks of DNA (cytosine and thymine) and RNA (uracil and cytosine) and are
essential for replication and transcription as well as repair. Pyrimidine activated sugars
are key intermediates in glycogen synthesis, glucuronidation reactions, protein and lipid
glycosylation as well as phospholipid synthesis.
There are two pathways leading to the synthesis of pyrimidines, the salvage
pathway and de novo biosynthesis pathway. In the salvage pathway, pyrimidine bases
from cellular degradation of RNA and DNA are reattached to ribose sugars, activated 5phosphoribosyl-1-pyrophosphate or PRPP, to yield UMP (uridine-5’-monophosphate) or
CMP (cytidine-5’-monophosphate) in a single enzymatic step [1]. These nucleotides are
further metabolized into all pyrimidine forms. The de novo biosynthesis pathway requires
glutamine, bicarbonate, ATP (adenosine-5’-triphosphate), aspartate, and PRPP for the
synthesis of UMP.
The de novo pyrimidine biosynthesis consists of six enzymatic reactions [2, 3]. The
first reaction in the pathway is catalyzed by glutamine-dependent carbamoyl phosphate
synthetase (CPSase, E.C. 6.3.5.5). CPSase catalyzes the formation of carbamoyl
phosphate from glutamine, two molecules of ATP, and bicarbonate. Carbamoyl
phosphate reacts with aspartate to form carbamoyl aspartate in a reaction catalyzed by
aspartate transcarbamoylase (ATCase, E.C. 2.1.3.2). Dihydroorotase (DHOase, E.C.
3.5.2.3) catalyzes the reversible condensation of carbamoyl aspartate to dihydroorotate,
which is then oxidized to orotate by dihydroorotate dehydrogenase. Orotate is coupled to
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PRPP to form orotidine-5’-monophosphate (OMP) through a reaction catalyzed by orotate
phosphoribosyl transferase (OPRTase). In the last step of the pathway, OMP is
decarboxylated by OMP decarboxylase (ODCase) to form UMP, the product of pyrimidine
biosynthetic pathway. UMP is further phosphorylated by UMP kinase to form UDP and
UTP by nucleoside diphosphate kinase. CTP synthetase catalyzes the formation of CTP
from UTP, ATP, and glutamine.

Figure 1: The de novo pyrimidine biosynthesis pathway
The de novo pyrimidine biosynthesis consists of six reactions leading to the formation of
Uridine-5’-monophosphate (UMP) from bicarbonate, glutamine, 2 ATP, aspartate and
PRPP. The reactions numbered in red are catalyzed by the following enzymes, (1)
carbamoyl phosphate synthetase, (2) aspartate transcarbamoylase, (3) dihydroorotase,
(4) dihydroorotate dehydrogenase, (5) orotate phosphoribosyl transferase, and (6) OMP
decarboxylase.
In mammals, the first three enzymes of pyrimidine biosynthesis are consolidated
on a single 243 kDa polypeptide, called CAD, combining CPSase, ATCase, and DHOase
domains [2]. The fourth enzyme, DHODHase, is an integral membrane protein present
on the outer leaf of mitochondrial inner membranes. OPRTase and ODCase activities,
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the fifth and sixth steps of the pathway, are catalyzed by a 53 kDa bifunctional protein
called UMP synthase [4]. In prokaryotes, these enzymes are expressed separately and
function independently or associate non-covalently to form multi-functional oligomers.
Due to the essential role of pyrimidines in various cellular reactions, defects in
pyrimidine biosynthesis can be devastating. For example, orotic aciduria, which is caused
by a disabling point mutation in UMP synthase, is characterized by megaloblastic anemia
and crystalluria [5], and is associated with defects in physical and intellectual
development [6]. Treatment for this disorder is the administration of uridine triacetate
which is then converted into UMP in the body.
1.1.1 Aspartate Transcarbamoylase
Aspartate transcarbamoylase (ATCase; EC 2.1.3.2) catalyzes the reaction of
carbamoyl phosphate (CP) and aspartate to form N-carbamoyl-l-aspartate (CA) and
inorganic phosphate [7] a key step in de novo pyrimidine biosynthesis. The catalytic
subunits or domains of all known ATCases in eukaryotes, prokaryotes and archaea have
a molecular mass of approximately 34 kDa and form stable homo-trimers under
physiological conditions.

Although ATCase is ubiquitous and catalyzes the same

reaction, the enzyme from different organisms is remarkably polymorphic, differing in
oligomeric structure, composition and regulatory properties.
ATCase is structurally organized as a part of 243 kDa CAD, combining CPSase,
ATCase, and DHOase, in Drosophila melanogaster [8] and Dictyostelium discoideum [9].
The ATCases from the fungi, Saccharomyces cerevisiae [10] and Neurospora crassa [11]
have a similar structural organization to CAD but lack DHOase activity. On the contrary,
Trypanosoma cruzi ATCase is not part of CAD and exists independently, representing an
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early progenitor in pyrimidine biosynthesis in the eukaryotic lineage before the gene
fusion event [12].
In prokaryotes, these enzymes are expressed separately and function
independently or associate non-covalently. The bacterial ATCase catalyzes the first
committed reaction in pyrimidine biosynthesis, and it is therefore highly regulated. Bethel
and Jones [13], have grouped the bacterial ATCases into three different families, A, B
and C, based on their molecular size and feedback regulation characteristics. Class A are
the largest with molecular size of 400-500 kDa dodecamers. Class A1 consist of active
ATCase and active dihydroorotase (DHOase), the third enzyme in the pathway, e.g.
Aquifex aeolicus [14, 15] Thermus aquaticus [16], and Streptomyces [17]. X-ray studies
of the A. aeolicus ATCase-DHOase complex have shown that two ATCase trimers are
held together by three DHOase dimers, an dodecameric structure reminiscent of the 32
symmetry of E. coli ATCase, but with the regulatory dimers replaced by dimers of DHOase
subunits [14, 15, 18]. In class A2 the active dihydroorotase is replaced by its inactive
homologue also known as pseudo-dihydroorotase as in Pseudomonas fluorescens [19],
Pseudomonas putida [20], and Pseudomonas aeruginosa [21]. The inactive pseudodihydroorotase maintains ATCase activity by conserving the dodecameric assembly of
the enzyme.
E. coli ATCase, the archetype ATCase, is designated as a class B enzyme. It is a
300 kDa heteromeric dodecamer consisting of six catalytic chains arranged into two
trimers and six regulatory chains arranged into three dimers [22-24]. The catalytic subunit
catalyzes the reaction and is not sensitive to nucleotides, whereas the regulatory subunit
binds nucleotides but does not exhibit catalytic activity. The enzyme undergoes feedback
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inhibition by CTP and UTP, the end products of the pathway, and activation by the purine
nucleotide, ATP, providing a balance between the synthesis of pyrimidines and purines.
X-ray studies (15-17) showed that two catalytic trimers are stacked above each other in
nearly eclipsed configuration and are held together by three regulatory dimers, which are
clustered around the periphery of the molecule.
Class C ATCases are the simplest and smallest in size with a molecular mass of
100 kDa. These ATCases are homotrimers of the catalytic subunit. They do not associate
with regulatory subunit or any other enzymes in the pathway. Class C ATCases lack
homotropic cooperativity and are insensitive to allosteric effectors, e.g. Bacillus subtilis
[25, 26]. X-studies [27] of B. subtilis ATCase showed that its tertiary structure is very
similar to the catalytic subunit of E. coli ATCase.
1.1.2 Dihydroorotase
Dihydroorotase (DHOase: E.C. 3.5.2.3) is a zinc metalloenzyme belonging to the
amidohydrolase family of enzymes [28]. It catalyzes the pH-dependent, reversible
cyclization of N-carbamoyl-L-aspartate into dihydroorotate, the third intermediate in de
novo pyrimidine biosynthesis.

Carbamoyl aspartate is favored above pH 6.2 and

dihydroorotate below [29]. Although all DHOases catalyze the same reaction in all
organisms, the enzyme adopts several different forms.
DHOases were initially classified into two distinct groups based on the
phylogenetic analysis [30]. Long (type I) DHOases are more ancient and larger in size
with a molecular mass of approximately 45 kDa. These DHOases function independently,
associate non-covalently with ATCase, e.g., Aquifex aeolicus DHOase [14, 31], or are
covalently linked with another enzyme in the pathway, e.g., CAD [2]. Short (type II)
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DHOases, e.g., E. coli DHOase, are smaller in size with a molecular mass of 38 kDa. A
more recent phylogenetic analysis reevaluated evolutionary relationships among
DHOases [32]. Long DHOases now include bacterial type I (Bacillus anthracis, A.
aeolicus, Thermus thermophilus, and Staphylococcus aureus) and III (Porphyromonas
gingivalis), animal CAD and CAD-like inactive DHOases from fungi, whereas the short
DHOases include active DHOases from fungi, bacterial type II (E. coli), and plant
DHOases. The long DHOases have one or two layered β-stranded adjacent domain that
clamps one lateral of the catalytic domain suggesting a stabilizing function. This adjacent
domain is not present in the short DHOases which only consist of the catalytic domain.
All DHOases have a TIM-barrel catalytic domain consisting of eight alpha helices and
eight beta strands, with catalytic residues at the carboxyl end of the barrel [28, 33]. The
archetypal metal center of DHOases is binuclear metal center with two zinc cations
separated by approximately 3.6 Å, e.g., E. coli and B. anthracis DHOase [34]. On the
contrary, S. aureus DHOase (PDB: 3GRI) [35] and A. aeolicus DHOase (PDB: 3D6N) [31]
have only one Zn2+ center whereas the DHOase domain of human CAD has three Zn2+
ions bound in the active site (PDB: 4C6M) [32]. In bacterial type II, III, and CAD DHOases,
the two Zn2+ are bridged by a carboxylated lysine, whereas in type I DHOase, the two
Zn2+ ions are bridged by an aspartate residue [36]. Another distinct feature is the flexible
loop that is present in all DHOases but bacterial type I DHOases [32]. This flexible loop
functions to seal the active site when the substrate, carbamoyl aspartate, is bound and
aids in catalysis by stabilizing the transition state, excluding solvent, and increasing the
substrate electrophilicity [37, 38]. Bacterial type I DHOase (A. aeolicus) has a shorter loop
that cannot seal the active site and interacts minimally with the substrate. The bacterial
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type I DHOase associates with ATCase to complete the active site with an electropositive
reaction chamber and attain full activity [15]. Additionally, loop 5 in bacterial type I
DHOase interacts with ATCase from the top of the barrel [15, 39], whereas in all other
DHOases, loop 5 is part of the dimerization interface [32] .
1.2 Pseudomonas aeruginosa
1.2.1 Pseudomonas aeruginosa and its Biology
Pseudomonas aeruginosa is a motile, Gram-negative bacillus, approximately 0.5
μm by 2 μ in size, with polar, monotrichous flagella. It is a highly versatile microorganism
that can adapt in variable environments and nutritional availability [40]. It is typically found
in soil and moist environments. P. aeruginosa is a non-fermentative, obligate aerobe that
derives its energy from oxidation of carbohydrates. It can also be a facultative anaerobe
and can use nitrate as a terminal electron acceptor in the absence of molecular oxygen
[41, 42]. Using the arginine dihydrolase pathway, P. aeruginosa can convert arginine to
ornithine and generate ATP [43]. P aeruginosa is mesophilic; it can grow at temperatures
ranging from 25-42 °C with an optimal growth temperature of 37°C [44]. P. aeruginosa
can be distinguished from other Pseudomonads by its production of pyocyanin, a blue
phenazine secondary metabolite, that gives blue-green color to pus from P. aeruginosa
infections and has been implicated in iron metabolism of P. aeruginosa [45].
1.2.2 Pathogenesis and Multi-Drug Resistance
P. aeruginosa is a highly opportunistic pathogen known to infect a wide range of
hosts, including plants, insects, and humans [46]. In humans, it can cause mild illness in
healthy individuals exposed to P. aeruginosa in poorly chlorinated hot tubs and pools or
from using extended-wear contact lenses [47]. P. aeruginosa is a common cause of
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nosocomial infections in immunocompromised patients with HIV [48] or cancer [49],
patients undergoing a transplant [50], patients who are mechanically ventilated [51], and
burn victims [52]. The common pseudomonal infections include infection of the soft tissue
from burns, open wounds, or post-surgery, infection of the urinary tract due to use of
urinary catheter, diabetic foot due to impaired microvascular circulation, otitis externa
(swimmer’s ear), keratitis, otitis media folliculitis (hot tub rash), bacteremia,
pneumonia/respiratory infection due to cystic fibrosis, COPD or chronic obstructive
pulmonary diseases, and mechanical ventilation [53]. P. aeruginosa is the main cause of
morbidity and mortality in cystic fibrosis patients [54].
The stages of prototype P. aeruginosa infection include, adherence, colonization,
invasion and dissemination, and systemic effects. P. aeruginosa has initial surface
interactions with the host cells using flagella and cell surface pili, the main adhesins that
enable binding to host cell membranes [55-57]. Once in contact with host cell membrane,
P. aeruginosa activates its type III secretion system and secretes effector proteins into
the host cell. These effector proteins interfere with signal transduction and cause
irreversible damage to host cell membrane resulting in alterations in host immune
responses and host cell necrosis [58, 59]. Once P. aeruginosa invades the host using its
cell surface proteins and exotoxins, it can adapt to the host environment by means of
quorum sensing and coordinating the expression of signaling molecules essential for
survival, colonization, and virulence [60, 61]. Quorum sensing is a density-dependent
signaling between cells through the production of autoinducer molecules. Quorum
sensing has been shown to play a role in P. aeruginosa biofilm formation [62, 63] which
causes persistent infections in cystic fibrosis patients. P. aeruginosa further invades the
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host system by expressing a wide range of virulence factors, including exotoxin A,
proteases, lipases, phospholipases, pyocyanin, and pyoverdine. Exotoxin A inhibits
elongation factor 2 (EF2) in the host and inhibits protein synthesis; proteases degrade
host complement factors and mucins, and disrupt intercellular junctions; lipases and
phospholipases degrade lipids in the host cell membrane; pyocyanin causes oxidative
stress in the host disrupting mitochondrial electron transport; pyoverdine is a siderophore
that sequesters iron from host depots and allows for a competitive edge in the host
environment where free iron is scarce [53, 64].
Multi-drug resistance of P. aeruginosa is increasing globally. P. aeruginosa has
intrinsic resistance to a wide variety of antimicrobial agents due to low outer membrane
permeability and efflux pumps pumping out macrolides, aminoglycosides, sulfonamides,
tetracyclines, chloramphenicol, β-lactams, and fluoroquinolones [65, 66]. Overexpression
of multiple efflux pumps has been found in several multi-resistant clinical isolates of P.
aeruginosa [67]. Moreover, acquisition of resistance genes through horizontal transfer or
mutational changes and decreased expression of outer membrane porin, OprD, have also
been implicated in P. aeruginosa resistance to β-lactams, aminoglycosides, and
carbapenem [68-70]. Adaptive resistance, including biofilm-mediated resistance and
generation of persister cells, during environmental stress in P. aeruginosa has been
attributed to tolerance of ciprofloxacin and tobramycin [71].
1.2.3 Current Therapeutics
The increase in antibiotic resistance among P. aeruginosa is associated with an
increase in patient morbidity. Studies [72, 73] have shown that combination therapy in
patients suspected of having pseudomonal infection leads to an increased likelihood of
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choosing an effective agent. Combining an anti-pseudomonal β-lactam with a second
anti-pseudomonal agent is suggested [74]. However, once susceptibility testing is
available, treatment should be deescalated to monotherapy to reduce the risk of
resistance selection.
Current empirical therapy for P. aeruginosa infections in patients with no assumed
risk factors includes carbapenem, ceftazidime, and aminoglycoside [74]. Newly
developed anti-Pseudomonal agents used clinically include, cefiderocol (cephalosporin),
ceftolozane-tazobactam or ceftazidime-avibactam (cephalosporin + β-lactamase
inhibitors), meropenem-vaborbactam (carbapenem + β-lactamase inhibitors) [74]. These
new drugs for P. aeruginosa infections have a good safety profile and tolerability, rapid
tissue distribution, and high activity against P. aeruginosa MDR strains, however, these
drugs have increased cost, no oral formulation, and carry a risk of more resistant bacterial
or fungal infection.
1.3 Staphylococcus aureus
1.3.1 Staphylococcus aureus and its Biology
Staphylococcus aureus is a member of the Micrococcaceae family. S. aureus is
Gram-positive cocci, measuring 0.5 µM to 1.5 µM in diameter, which occur singly, in pairs,
as short chains or in grape-like clusters [75]. S. aureus can grow in temperatures ranging
from 7-48 °C with an optimum temperature of 37 °C. S. aureus naturally colonizes the
skin, nasal passage, and axillae [76]. S. aureus is a facultative anaerobe; it can upregulate
glycolysis and fermentation [77] and can readily use nitrate as the final electron acceptor
under hypoxic conditions [78]. It can be distinguished from other Gram-positive cocci by
anaerobic fermentation of glucose, and positive catalase and coagulase tests. S. aureus
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is catalase positive and produces bubbles upon addition of a few drops of 3% hydrogen
peroxide [76]. It is also coagulase positive and coverts soluble fibrinogen in plasma into
insoluble fibrin. It is non-motile and non-spore forming [79] and produces microcapsules
[80].
1.3.2 Pathogenesis and Multi-Drug Resistance
S. aureus is a commensal microorganism but also a serious pathogen. It is the
most common cause of community-acquired and nosocomial infections. Everyone is
susceptible to S. aureus infections; however, certain groups of people are at a greater
risk, including patients with weakened immune system, diabetes, cancer, lung disease,
or eczema and patients hospitalized in the intensive care units and with medical devices
inserted in their bodies [81]. S. aureus causes a multitude of infections, including
superficial mild cutaneous abscesses and impetigo to more invasive and life-threating
pneumonia, osteomyelitis, bacteremia, endocarditis, sepsis, and toxic shock syndrome
[82].
S. aureus infection usually results from a breach of the skin, the first line of
defense, enabling the entry of bacteria into the underlying tissue. Once inside the host
tissue, S. aureus overcomes the challenge of adhering to host tissue by expressing many
surface protein adhesins called “microbial surface components recognizing adhesive
matrix molecules” (MSCARMMs) [83]. These MSCARMMs bind to components of the
extracellular matrix namely fibronectin, collagen, and fibrinogen, and facilitate tissue
attachment. S. aureus can evade the host immune system in numerous ways. S. aureus
shields its surface and impedes phagocytosis by polymorphonuclear leukocytes (PMNs)
by expressing a polysaccharide microcapsule surrounding its cell wall [84]. It further
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inhibits oposonization and phagocytosis by expressing protein A on the cell wall. Protein
A binds to the Fc region of host IgG resulting in incorrectly oriented IgG that cannot be
recognized by neutrophils [85]. S. aureus has been shown to inhibit neutrophil chemotaxis
and recruitment toward complement activation by secreting chemotaxis inhibitory protein
(CHIP) [86]. It secretes membrane-damaging polypeptides, notably α-hemolysin, a poreforming exotoxin that targets multiple cell types and primarily causes cell lysis by allowing
flow of ions and low molecular weight molecules through the amphipathic pore in the
plasma membrane [87]. α-hemolysin has also been shown to delay corneal wound
healing in keratitis and promote intracellular invasion of S. aureus [88]. S. aureus further
invades the host tissue through a variety of extracellular enzymes that cause tissue
destruction facilitating bacterial penetration into the tissue. A few of these enzymes
include,

proteases,

lipases,

nucleases,

hyaluronate

lyase,

phospholipase

C,

metalloproteases [89]. S. aureus infections can be highly persistent and recurrent. S.
aureus can form multilayered biofilm allowing a protected mode of growth, antibiotic
resistance, and seeding dispersal to other sites [90]. S. aureus also has the ability to
switch phenotype from normal colony phenotype (NCP) to a dormant small-colony
variants (SCVs) phenotype. These SCVs can persist intracellularly in a protective niche
from host immune system and antibiotics [91, 92]. SCVs are a result of selective pressure
in the host environment, and they can revert to the parental phenotype after the
discontinuation of antibiotic treatment.
S. aureus is notorious for developing multi-drug resistance. The first wave of
resistance was seen during S. aureus resistance to penicillin that was mediated by βlactamase. β-lactamase, encoded by blaZ gene, inactivates β-lactam antibiotics by
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hydrolyzing the β-lactam ring [93]. The discovery of penicillase-resistant methicillin marks
the onset of second wave of resistance. Methicillin resistance in S. aureus was first
discovered by Jevons in 1961 [94] only two years after methicillin was introduced. The
rise of methicillin resistant S. aureus (MRSA) is thought to have originated due to the
horizontal transfer of mecA gene between S. aureus and another staphylococcal species
[95]. mecA encodes for penicillin-binding protein, PBP2a, which has a lower affinity for βlactam antibiotics compared to native PBP [96, 97]. Consequently, peptidoglycan crosslinking is not affected in MRSA. Methicillin resistance is a broad beta-lactam antibiotic
class that is resistant to penicillin, cephalosporin, and carbapenem. Since 1970s, new
MRSA strains have emerged including, MRSA II, III, and IV, community acquired (CA)
MRSA, and hospital acquired (HA) MRSA, causing worldwide pandemic. The dramatic
increase in vancomycin used to treat MRSA infections has inevitably triggered
vancomycin resistance in S. aureus. Vancomycin intermediate-resistant S. aureus (VISA)
carries several spontaneous mutations [98] that increase peptidoglycan synthesis and
abnormally thick cell wall hindering vancomycin penetration into the cell [99]. Vancomycin
resistant S. aureus (VRSA) is suggested to have resulted from conjugal transfer of vanA
operon from a vancomycin-resistant Enterococcus faecalis [100]. In these isolates, with
the presence of vanA, there is an alteration in the terminal peptide from D-Ala-D-Ala to
D-Ala-D-Lac in the peptidoglycan resulting in reduced affinity to vancomycin and
continuous peptidoglycan assembly [93].
1.3.3 Current Therapeutics
The therapeutic approach for S. aureus infections is based on the site and source
of infection as well as on the detection of metastatic spread [101, 102]. Generally, the
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infections caused by methicillin-sensitive S. aureus infection are treated by β-lactams,
carbapenams, and cephalosporins. Methicillin-resistant S. aureus infection is commonly
treated with vancomycin, a glycopeptide antibiotic. However, vancomycin must be given
through IV, it is not absorbed if given orally. Other alternatives in case of treatment failure
include linezolid and daptomycin. Linezolid is a new FDA-approved drug, an
oxazolidinone antibiotic that has activity against methicillin-resistant as well as
vancomycin-resistant S. aureus infections and is available in oral form with 100%
bioavaibility [103, 104]. Another oxazolidinone that has been licensed for short-term
treatment is tedizolid. Tedizolid binds to the 50S subunit of the bacterial ribosome and
inhibits protein synthesis [105]. Daptomycin is a cyclic lipopeptide antibiotic for methicillinsusceptible, methicillin-resistant, and vancomycin-resistant S. aureus. Daptomycin kills
by causing rapid depolarization of the bacterial cell membrane [106]. Three new
lipoglycopeptides including, dalbavancin, oritavancin, and telavancin, have been
approved by the FDA for skin and soft tissue infections.
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CHAPTER 2: MATERIALS AND METHODS
2.1 PCR and Cloning
The genes encoding S. aureus ATCase and DHOase were cloned into
pMCSG19C vector. These plasmids were a generous gift from Dr. Joseph Brunzelle at
Northwestern University, IL.
The pyrB gene encoding Pseudomonas aeruginosa (PAO1 strain) ATCase was
amplified by polymerase chain reaction (PCR) using forward primer: 5’ CAT CAT CAC
CAC CAT CAC CCG ACA GAC GCC AAG CGC CCG 3’ and reverse primer: 5’ GTG
GCG GCC GCT CTA TTA TTC GGC GTC CTC CTG TTC CAG 3’. The pyrX gene
encoding P. aeruginosa pDHO was amplified using forward primer: 5’ CAT CAT CAC
CAC CAT CAC ACC ATC AGT ATC CGA GGC GCC 3’ and reverse primer: GTG GCG
GCC GCT CTA TTA GCC CTC GTG GGT CAG GTG TCC 3’. The resulting PCR products
were cloned separately into T7 pETite (Lucigen, catalog: 49001-1), an expression vector
that incorporates a 6xHis tag on the amino end of the recombinant protein. The pETite
vector and PCR product were co-transformed into HI-Control 10G chemically competent
cells. pETite vector is provided in a linear form allowing recombination between the vector
and PCR product within the host strain fusing the gene of interest to the vector.
2.2 Expression and Isolation of the Recombinant Proteins
The constructs were transformed separately into E. coli Hi-Control BL21(DE3) cells
for protein expression. The transformants were grown at 37°C in LB medium until OD600
(optical density at 600 nm) of 0.6 and protein expression was induced by addition of 0.1
mM isopropylthio-β-D-galactoside (IPTG) followed by overnight (16-18 hours) incubation
at 20°C. The cells were harvested by centrifugation and resuspended in binding buffer
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consisting of 50 mM sodium phosphate, pH 7.5, 500 mM NaCl, and 5% glycerol. The cells
were lysed by sonication and then passed through a French press. The cell lysate was
centrifuged at 12,000 x g for 30 minutes at 4°C. The soluble fraction was applied to 5.0ml Ni2+ Probond affinity column (Invitrogen) after equilibrating the column with ten column
volumes of the binding buffer. The column was then washed three times with 10 column
volumes of buffer containing increasing concentrations of imidazole, 0 mM imidazole, 25
mM imidazole, and 50 mM imidazole, and the proteins were eluted in 5-mL aliquots with
250 mM imidazole in the same buffer. The fractions were analyzed by electrophoresis on
12% SDS-PAGE gels [107]. Pure protein fractions were pooled and concentrated in the
Amicon Ultra-15 centrifugal filter units (EMD Millipore, catalog: UFC901008). Protein
concentrations were then determined by the Lowry method [108] using bovine serum
albumin as a standard.
2.3 Size-Exclusion Chromatography
The molecular mass of the recombinant proteins was determined by size-exclusion
on an ÄKTA Prime Plus chromatography system. The Ni2+ column purified pDHO/DHO,
ATCase, and the ATCase-pDHO/DHO complex, reconstituted by mixing equimolar
amounts of individual proteins, were applied to an ÄKTA Superdex S200 column
equilibrated with 50 mM Tris-HCl, pH 7.5, 200 mM NaCl, and 5% glycerol. A 0.5-2.0 mL
sample of purified protein, 5-10 mg/mL, was applied and eluted with the same buffer at a
flow rate of 0.5 mL/min. The protein fractions were analyzed by electrophoresis on 12%
polyacrylamide gel. The column was calibrated with a mixture of standard proteins (BioRad, catalog: 1511901) with molecular weights from 1.3 –670 kDa and the mass of the
eluted species was determined from plots of log (MW) versus elution volume.
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2.4 Protein Quantification
The colorimetric Lowry protein assay [108] was used for the quantification of the
proteins. A standard curve of 0 to 100 µg of bovine serum albumin (BSA) was prepared
in 200 µL from 1 mg/mL BSA stock solution. The protein samples (3, 5, and 7 µL) were
diluted in 200 µL water. Alkaline copper reagent consisting of 0.02 Na/K tartrate, 0.01%
CuSO4.5H2O, and 1.96 % Na2CO3 in 0.1 N NaOH was prepared from stock solutions of
2% Na/K tartrate, 1% CuSO4.5H2O and 2% Na2CO3 in 0.1 N NaOH. 800 µL of alkaline
copper reagent was added to all standard and sample tubes. The tubes were vortexed
and incubated for 15 minutes at room temperature. Folin and Ciocalteu’s phenol reagent
(Sigma, Catalog: F9252) was diluted 1:1 with water and 100 µL of diluted reagent was
added to all tubes. The tubes were vortexed and incubated for 30 minutes at room
temperature. The absorbance was measured at 750 nm and plotted as a function of BSA
concentration. The protein concentrations of the three samples were determined using
the standard curve
2.5 Enzyme Assay
ATCase activity was measured by the colorimetric method as previously described
by Prescott and Jones [109, 110]. The reaction mixture to measure carbamoyl aspartate
saturation curve of ATCase consisted of 8 mM aspartate, 50 mM Tris/acetate buffer, pH
8.3, and 1-4 µg of purified ATCase and variable (0-10 mM) carbamoyl phosphate in a
total volume of 1 mL. The reaction mixture for aspartate saturation consisted of 10 mM
carbamoyl phosphate, 50 mM Tris/acetate buffer, pH 8.3, 1-4 µg of purified ATCase and
variable (0-15 mM) aspartate in a total volume of 1 mL. In P. aeruginosa ATCase activity
assay samples, an equimolar amount of pDHO was present. Samples were pre-incubated
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at 37°C for 1 min. The reaction was then initiated by the addition of carbamoyl phosphate
or aspartate, 0-15 mM, and allowed to proceed for 2 min. The reaction was quenched by
the addition of 1 mL of 5% acetic acid. Then 2 mL of color mix containing
antipyrine/diacetyl monooxime in a 2:1 ratio was added, and the assay mixture was
heated at 60°C for 60 min for color development. The carbamoyl aspartate generated by
ATCase is converted into a yellow chromophore and the absorbance was measured at
466 nm.
DHOase activity for S. aureus DHOase was determined by measuring the reverse
reaction, the formation of carbamoyl aspartate from dihydroorotate at pH 8.3. The reaction
mixture to measure dihydroorotate saturation of DHOase consisted of 50 mM Tris/acetate
buffer, pH 8.3, and 1-4 µg of purified DHOase and variable (0-8 mM) dihydroorotate in a
total volume of 1 mL. Samples were pre-incubated at 37°C for 1 min. The reaction was
then initiated by the addition of dihydroorotate and allowed to proceed for 2 min. The
reaction was quenched with 1 mL of 5% acetic acid, and the samples were processed
hereafter as mentioned for the ATCase assay above.
2.6 Chemical Cross-linking
Bis(sulfosuccinimidyl)suberate (BS3) (Thermo Scientific, catalog: 21580), noncleavable amine-to-amine cross-linker, was freshly prepared by adding 2 mg of crosslinker to 70 µL water giving a 50 mM stock. Purified recombinant ATCase (45 µM) or
pDHO (37 µM) in 50 mM sodium phosphate, pH 7.5, 500 mM NaCl, and 5% glycerol was
cross-liked

for

up

to

2

hours

at

room

temperature

with

5

mM

bis(sulfosuccinimidyl)suberate as a final concentration. For cross-linking of ATCasepDHO complex, ATCase (36µM) and pDHO (37 µM) in 50 mM sodium phosphate, pH
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7.5, 500 mM NaCl, and 5% glycerol were crosslinked for the indicated times with 5 mM
bis(sulfosuccinimidyl)suberate. The reaction was quenched by adding 10 µL of 1 M TrisHCl, pH 8 and sample buffer consisting of 12 mM Tris-HCl, pH 6.8, 5% glycerol, 0.4%
SDS, 2.88 mM β-mercaptoethanol, and 0.02% bromophenol blue. The samples were
boiled at 100°C for 7 minutes and the cross-linked species were analyzed by SDS
electrophoresis on 7.5% or 4-20% gradient polyacrylamide gel.
2.7 Thermal Shift Assay
Thermal shift assay using Applied Biosystems 7500 Real-time PCR system was
performed to determine the thermal stability of the proteins. The final concentrations of
individual subunits. ATCase and pDHO, ATCase-pDHO complex, and the SYPRO
Orange (1000X stock, Invitrogen, Catalog: S6651) were optimized to 0.1 mg/mL, 0.05
mg/mL, and 20X, respectively [111]. The total reaction volume was 25 µL that was made
up the addition of buffer consisting of 50 mM Tris, pH 7.5, and 200 mM NaCl. 200 µM
PALA, 10 mM ATP, or 0-1 mM top-ranking FDA-approved compounds were present in
the well where indicated. The microplate was sealed with an adhesive optical clear seal
and centrifuged for 60 seconds at 1000 x g before placing in the instrument. The thermal
shift assay was run from 25 to 95 °C with a ramp speed of 0.5°C/min. The melting
temperature was determined using the 7500-software.
2.8 Polyacrylamide Gel Electrophoresis
Polyacrylamide gel electrophoresis were carried out using the Laemmli system
[107], which uses a discontinuous buffer system. The acrylamide/bis-acrylamide
percentage in all the separating gels varied from 4-20% gradient, 7.5% or 12% nongradient depending on the size of the proteins separated. 7.5% acrylamide/bis-acrylamide
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gels were typically used when analyzing ATCase-DHO complex formation. 0.1% SDS
was present in all SDS gels and the electrophoresis buffer contained 0.192 M glycine,
0.025 M Tris-HCl, pH 8.3, and 0.1% SDS. The samples were boiled for 7 minutes at
100°C in sample buffer consisting of 12 mM Tris-HCl, pH 6.8, 5% glycerol, 0.4% SDS,
2.88 mM β-mercaptoethanol, and 0.02% bromophenol blue. The electrophoresis was
carried out at a constant voltage of 150 V on ice until the dye front reached the bottom of
the gel.
All native gels [112] consisted of 7.5% acrylamide/bis-acrylamide with or without
10 mM ATP or 10 mM sodium pyrophosphate and no SDS. The electrophoresis buffer
contained 0.192 M glycine and 0.025 M Tris-HCl, pH 8.3. ATP (10 mM) or sodium
pyrophosphate (10 mM) was present in the electrophoresis buffer when running gel with
ATP or sodium pyrophosphate present in the gel matrix. The samples for native gel
electrophoresis were prepared in the sample buffer containing 12 mM Tris-HCl, pH 6.8,
5% glycerol, and 0.02% bromophenol blue. The native gel electrophoresis was carried
out at a constant voltage of 150 V for 55 minutes on ice.
2.9 Crystallization, Data Collection, and Structure Refinement
All proteins were gel-filtered in buffer containing 50 mM Tris-HCl, pH 7.5, 200 mM
NaCl, and 1 mM dithiothreitol prior to crystallization. The crystals were grown at room
temperature using the sitting-drop, vapor diffusion method by mixing the protein with an
equal volume of reservoir solution. The crystals were harvested by soaking in a
cryoprotectant solution consisting of mother liquor and 20% ethylene glycol prior to
freezing in liquid nitrogen. X-ray diffraction data were collected at the Advanced Photon
Source, Argonne National Laboratory in Illinois, and processed and scaled using the
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program XDS [113]. The crystal structures were solved by the molecular replacement
method with the program PHASER within the Phenix suite [114]. Structure modeling was
carried out in COOT [115] and refinement was performed using Phenix and PDB-Redo
[116]. The final structure was validated with Molprobity [114].
2.10 Programs used for Various Applications
Table 1: List of Programs
Program

Application

Phenix [114]

Xtriage: used to analyze diffraction data to assess quality and
detect possible problems
Phaser: Used for molecular replacement
Autobuild: Used for automated model building
Refine: Used to refine the structure by improving the fit of the
model to the data
MolProbity: To produce geometric validation statistics

PDB-Redo [116]

PDB-Redo Server: Optimizes refinement settings, refines, and
partially rebuilds structure, and validates the results

Coot [115]

Used for model building, model manipulations, and validation

Yasara [117]

Used for molecular visualization

MOE [118]

Used for molecular visualization and virtual screening

PISA [119]

Used to calculate protein interfaces and assembly
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CHAPTER 3: CHARACTERIZATION AND ASSEMBLY OF THE
PSEUDOMONAS AERUGINOSA ASPARTATE-TRANSCARBAMOYLASEPSEUDO DIHYROOROTASE COMPLEX
3.1 Abstract
Pseudomonas aeruginosa is a virulent pathogen that has become more
threatening with the emergence of multidrug resistant strains.

The aspartate

transcarbamoylase (ATCase) of this organism is a dodecamer comprised of six 37 kDa
catalytic chains and six 45 kDa chains homologous to dihydroorotase (pDHO) but
inactive. The pDHO chain itself has no catalytic activity but is necessary for ATCase
activity. Here we have cloned and expressed both P. aeruginosa subunits. A
stoichiometric mixture of the two proteins associates into a dodecamer with full ATCase
activity. Unlike the catalytic subunit of other known ATCases, the P. aeruginosa catalytic
chain does not spontaneously assemble into a trimer. Chemical crosslinking and sizeexclusion chromatography clearly showed that protein remains monomeric which
accounts for its lack of catalytic activity since the active site is a composite comprised of
residues contributed by adjacent monomers in the trimer. Circular dichroism spectroscopy
indicated that the ATCase chain folds into a well-defined structure although neither the
ATCase nor the pDHO subunits are very stable as determined by a thermal shift assay.
However, formation of the complex increases the melting temperature by about 30°C.
Another unusual characteristic is that the ATCase is strongly inhibited by all nucleotide
di- and triphosphates and exhibits extreme cooperativity. Previous studies suggested
that the regulatory site is in an 11-residue extension of the amino end of the ATCase
chain. However, deletion of the extensions of both the amino and carboxyl ends of the
polypeptide did not affect catalytic activity, nucleotide inhibition or the assembly of the
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dodecamer. Nucleotides destabilized the dodecamer which can probably account for the
inhibition and extreme cooperativity of the substrate saturation curves. In contrast to
previous interpretations, these results suggest that P. aeruginosa ATCase is not
allosterically regulated by nucleotides.
3.2 Introduction
Pseudomonas aeruginosa is a ubiquitous, saprophytic microorganism that
normally inhabits the soil and aquatic environments. It is an opportunistic pathogen that
can infect a wide variety of hosts including plants, nematodes, insects, and animals [120].
P. aeruginosa is the leading cause of nosocomial infections in immunocompromised
patients and is most commonly associated with ventilator-associated pneumonia and
burn wound infections with a high mortality rate [121]. P. aeruginosa is the most common
cause of respiratory failure and death in patients with cystic fibrosis [122]. Treating P.
aeruginosa infections is challenging due to increasing resistance of P. aeruginosa to
existing therapeutics.
Aspartate transcarbamoylase (ATCase; EC 2.1.3.2) catalyzes the reaction of
carbamoyl phosphate (CP) and aspartate to form N-carbamoyl-l-aspartate (CA) and
inorganic phosphate, a key step in de novo pyrimidine biosynthesis [7]. P. aeruginosa
ATCase belongs to class A2 ATCases. The first class A2 ATCase was purified by Adair
and Jones [123] from Pseudomonas fluorescens, who found that the protein was a dimer
composed 180 kDa subunits and that it was inhibited by ATP, CTP and UTP. In view of
the unusual subunit structure that suggested that the catalytic unit is not trimeric, we reexamined the size, composition and regulation of P. fluorescens ATCase [19]. In this
study, isolated P. fluorescens ATCase was found to be a 460 kDa dodecamer composed
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of six copies of a 34 kDa catalytic trimer and six copies of a 45 kDa subunit of unknown
function. The function of the isolated subunits could not be ascertained because they
could not be separated without denaturation and loss of ATCase activity. However, the
34 kDa polypeptide was shown to be an ATCase catalytic chain by affinity labelling of the
active site with the competitive inhibitor, [14C]-pyridoxal phosphate followed by sodium
borohydride reduction. Schurr et al. [124] subsequently sequenced the 45 kDa subunit
and showed that it was pDHO.
We then investigated the ATCase from P. aeruginosa [21] and found that it had
the same subunit structure and putative regulatory properties. All oxy- and
deoxynucleotide triphosphates strongly inhibited the enzyme. Free GTP and ATP, but not
the Mg2+ATP, inhibited the enzyme. It is difficult to reconcile these results with the
proposed function of allosteric regulation of ATCases, namely, to balance the levels of
pyrimidines and purines.
We report here the overexpression and purification of P. aeruginosa ATCase and
pDHO, and determination of oligomeric states of individual proteins to better understand
the assembly of the dodecamer. Unlike the ATCase from other organisms, the catalytic
unit is monomeric and only becomes a catalytically active trimer when it associates with
pDHO. Successful purification and crystallization of the P. aeruginosa ATCase-pDHO
complex enhances our knowledge of class A2 ATCases and represents a new target to
develop antipseudomonal therapies.
3.3 Materials and Methods
3.3.1 CD Spectrometry
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The CD spectra of pDHO (1.8 µM), ATCase (2.67 µM), and the ATCase-pDHO
complex (1.8 µM) prepared by mixing stoichiometric amounts of pDHO and ATCase, were
obtained in the wavelength range of 185-300 nm using a Jasco CD spectrophotometer.
The proteins were prepared in 5 mM sodium phosphate, pH 8.
3.3.2 Controlled Proteolysis by Elastase
Purified recombinant ATCase was subjected to controlled proteolysis at 37°C at a
protein-to-elastase ratio (wt/wt) of 250. The reaction mixture consisted of 160 µg of
ATCase or 160 µg of ATCase-pDHO complex and 0.64 µg of elastase per 160 µL in 50
mM Tris-HCl, pH 8, and 200 mM NaCl with or without 100 µM PALA. Samples were taken
periodically over 60 minutes and quenched by adding 5 µL of sample buffer consisting of
12 mM Tris-HCl, pH 6.8, 5% glycerol, 0.4% SDS, 2.88 mM β-mercaptoethanol, and 0.02%
bromophenol blue, and by heating for 7 min at 100°C. The samples were analyzed by
electrophoresis on SDS 12% polyacrylamide gel.
3.3.2 Crystallization, Data Collection, and Refinement
Prior to crystallization, 200 µM N-phosphonacetyl-L-aspartate (PALA) was added
to gel-filtered delN ATCase-pDHO complex in 50 mM Tris-HCl, pH 7.5, 200 mM NaCl,
and 1 mM dithiothreitol. All crystals were grown at room temperature using the sittingdrop, vapor diffusion method. 1 µL of Ndel ATCase-pDHO - PALA solution was mixed
with 1 µL of reservoir solution containing 20% polyethylene glycol 10,000, 0.1 M
hydroxyethyl-piperazineethane-sulfonic acid or HEPES buffer, pH 7.5, and 1 mM
Anderson−Evans polyoxotungstate [TeW6O24]6− (TEW). Crystals that grew within two
weeks were then used for preparing seed stock for performing subsequent seeding
experiments as follows: 2 µL of the drop solution - including the crystals - was added to
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50 µL of reservoir solution in a microcentrifuge tube with Seed Bead (Hampton) and
vortexed for 3 minutes to generate seed stock. One µL of 1:4 diluted seed stock was
mixed with one µL of 1 mg/mL delN ATCase-pDHO-PALA solution to allow crystal growth
at room temperature using the sitting-drop, vapor diffusion method. The best diffracting
cubic crystals grew to 0.1 mm x 0.1 mm within 2-4 days. The crystals were soaked in a
cryoprotectant solution consisting of 25% polyethylene glycol 10,000, 0.1 M hydroxyethylpiperazineethane-sulfonic acid or HEPES buffer, pH 7.5, and 1 mM Anderson−Evans
polyoxotungstate [TeW6O24]6− (TEW), 200 µM PALA, and 20% ethylene glycol prior to
freezing in liquid nitrogen. X-ray diffraction data were collected at the Advanced Photon
Source, Argonne National Laboratory in Illinois. The crystals belong to the space group
H32 (No. 155) and diffracted to 2.47 Å resolution, with one delN ATCase, one pDHO, and
two molecules of TEW in the asymmetric unit. The structure was solved by the molecular
replacement method using the PHASER application within the Phenix suite from
uncomplexed homology models of ATCase and pDHO. Structure modeling was carried
out in COOT and refinement was performed using Phenix.
3.4 Results
3.4.1 Cloning, Expression, and Purification of P. aeruginosa ATCase and pDHO
The pyrB gene encoding P. aeruginosa ATCase and the pyrX gene encoding
pDHO from strain PAO1 were separately amplified by PCR and inserted into the pETite
vector, which incorporates a 6x His tag on the amino terminus of the proteins. The
resulting constructs were then transformed into E. coli Hi-Control BL21(DE3) cells. The
proteins were expressed and purified as described in chapter 2. Although significant
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amounts of both proteins formed inclusion bodies, the soluble proteins were both
expressed at 40 mg/liter (Fig. 2A and B).

Figure 2: Expression and Purification of P. aeruginosa ATCase and pDHO.
The genes encoding P. aeruginosa ATCase (pyrB) and pDHO (pyrX) were separately
cloned into pETite (Lucigen), an expression vector that incorporates a 6xHis tag on the
amino end of the recombinant proteins. The resulting constructs were transformed
separately into E. coli Hi-Control BL21(DE3) cells (Lucigen). The transformants were
grown at 37°C in LB medium until OD600 of 0.6 and induced with 0.1 mM IPTG overnight
(16-20 hours) at 20°C. The cells were harvested and resuspended in 50 mM sodium
phosphate and 0.5 M NaCl, pH 7.5, and passed twice through a French press. The cell
lysate was centrifuged at 12,000 x g for 45 minutes at 4°C. The supernatant was applied
to 5.0 ml Ni2+ affinity column. The column was washed with 10 column volumes with
increasing concentration of imidazole up to 100 mM. the proteins were eluted in 5 mL
aliquots with 250 mM imidazole in the same buffer. A) ATCase and B) pDHO fractions
were analyzed by electrophoresis on 12% SDS-PAGE Laemmli gels; S: protein standard,
P: pellet, L: lysate, F: flow-through.
3.4.2 Oligomeric Structure of P. aeruginosa ATCase and pDHO
On SDS-PAGE, under denaturing conditions, ATCase had an estimated molecular
mass of 36 kDa, in agreement with the mass calculated from the amino acid sequence.
ATCase purified by nickel affinity chromatography was then subjected to gel filtration
chromatography on a calibrated Superdex S200 column. ATCase eluted as a single
species with a molecular mass of 37 kDa indicating that it is monomeric (Fig. 3A & B).
The isolated pDHO monomer had a molecular mass of 45 kDa on denaturing SDS gels
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but eluted as a 90 kDa species on the S200 size exclusion column indicating that it forms
stable dimer (Fig. 3C & D).

Figure 3: Oligomeric Structure of P. aeruginosa ATCase and pDHO
A) Purified P. aeruginosa ATCase was subjected to size-exclusion chromatography on a
Superdex S200 Akta column and B) the fractions, F20, F21, and F22, corresponding to
the ATCase peak were analyzed by 12% SDS-PAGE. C) Purified P. aeruginosa pDHO
was subjected to size-exclusion chromatography. D) Fractions F17, F18, and F19
corresponding to pDHO peak were analyzed by 12% SDS-PAGE.
3.4.3 Chemical Cross-linking
The oligomeric structure of the proteins was also examined by chemical
crosslinking. In agreement with the size exclusion chromatography, crosslinking of the
ATCase subunit with BS3 (bis(sulfosuccinimidyl)suberate) for up to two hours, showed
that the protein remained monomeric (37 kDa) although trace amounts of a higher
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molecular species were visible (Fig. 4A). Although size exclusion chromatography
showed that the pDHO is dimeric, no crosslinked species were observed (Fig. 4B). This
result suggested that the pDHO dimer cannot undergo crosslinking because the lysines
are not located near the dimer interface of pDHO.

Figure 4: Chemical Crosslinking of P. aeruginosa ATCase and pDHO
A) Purified recombinant ATCase (45 µM) in 50 mM sodium phosphate, pH 7.5, and 500
mM NaCl, was cross-linked for the indicated times with 5 mM
bis(sulfosuccinimidyl)suberate. The reaction was quenched by adding 10 µL of 1 M TrisHCl, pH 8. Cross-linked species were analyzed by electrophoresis on a 7.5%
polyacrylamide gel. B) chemical crosslinking of pDHO as described for ATCase.
3.4.4 Isolation and Composition of the ATCase-pDHO Complex
The isolated ATCase subunit lacked catalytic activity. However, titration of the
purified ATCase subunit with pDHO subunit restored the latent catalytic activity (Fig. 5A).
ATCase activity increased linearly with increasing amounts of pDHO until a molar ratio of
ATCase to pDHO was 1:0.97, and the activity then leveled off as pDHO binding site on
ATCase became saturated.
The P. aeruginosa complex was reconstituted by mixing an equimolar ratio of the
ATCase and pDHO subunits. The reconstituted complex was then subjected to gel
filtration chromatography on a calibrated Superdex S200 column. The ATCase-pDHO
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complex eluted in single peak with a molecular mass of 457 kDa (Fig. 5B & C). SDS gel
electrophoresis confirmed that the complex consisted of equimolar amounts of the two
subunits. Furthermore, individual ATCase, pDHO, and ATCase-pDHO complex were
subjected to native gel electrophoresis. The isoelectric points of ATCase and pDHO are
6.36 and 5.46, respectively. Laemmli’s gel system without SDS at pH 8.3 was used to
analyze these acidic proteins for native PAGE. The ATCase-pDHO complex had a band
very distinct from individual subunits at a molecular weight of 480 kDa approximately (Fig.
5D), confirming oligomerization of ATCase and pDHO as shown by size exclusion
chromatography.
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Figure 5: Formation of the ATCase-pDHO Complex.
A) A fixed constant amount of ATC (4 µg) was titrated with increasing amounts of pDHO
(0-24.3 µg). The ATCase activity was measured at 37°C as described in chapter 2. B)
Purified recombinant ATCase and pDHO were mixed in an equimolar ratio and the
complex was analyzed by size-exclusion chromatography on a Superdex S200 column.
C) Fractions F13 and F14 corresponding to the complex peak were analyzed on 12%
SDS-PAGE. D) 7.5% native gel with ATCase, pDHO, and ATCase-pDHO complex (DAC).
Chemical cross-linking of the A. aeolicus ATCase-and DHOase with DMS dimethyl
suberimidate gave a limited number of crosslinked species (Fig. 6A) [14]. Crosslinking of
the P. aeruginosa ATCase-pDHO with BS3 (bis(sulfosuccinimidyl)suberate) showed
additional species suggesting a more complex assembly/disassembly pathway (Fig. 6B).
In the absence of the crosslinking reagent, the P. aeruginosa complex was fully
dissociated on the SDS gel into the constituent subunits (Fig 6B, lane 3). After the addition
of the crosslinker, many more partial species were trapped, suggesting more complex
association/dissociation pathway. An identical profile of crosslinked species was
reproducibly obtained in eight crosslinking experiments.

Figure 6: Assembly of the ATCase-pDHO complex
A) Chemical cross-linking of A. aeolicus ATCase and DHOase with DMS dimethyl
suberimidate, Ahuja et al. [14]. B) Purified recombinant P. aeruginosa ATCase (36 µM)
and pDHO (37 µM) in 50 mM sodium phosphate, pH 7.5, and 500 mM NaCl, were crosslinked for the indicated times with 5 mM bis(sulfosuccinimidyl)suberate. The reaction was
quenched by adding 10 µl of 1 M Tris-HCl, pH 8. Cross-linked species were analyzed by
electrophoresis on a 7.5% polyacrylamide SDS gel.
3.4.5 Steady State Kinetics
The ATCase steady state kinetics parameters were obtained from carbamoyl
phosphate (Fig. 7A) and aspartate (Fig. 7B) saturation curves. As previously reported, P.
aeruginosa ATCase was found to be inactive in the absence of pDHO. Activity was
restored by the addition of an equimolar amount of pDHO to the assay mixture. The
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carbamoyl phosphate saturation curve of P. aeruginosa ATCase-pDHO complex was
sigmoidal. A least square fit of the data to the Hill equation gave a K m for carbamoyl
phosphate ([S]0.5) of 2.5 mM and a Vmax of 142 µmoL/min/mg (Table 2). The aspartate
saturation curve of ATCase-pDHO had a Km for aspartate of 3.6 mM and a Vmax of 183
µmoL/min/mg. Both aspartate and carbamoyl phosphate saturation curves exhibit modest
sigmoidicity. The bi-substrate inhibitor N-phosphonacetyl-L-aspartate (PALA) is also a
potent inhibitor of the of the P. aeruginosa enzyme. Although PALA is a competitive
inhibitor of the ATCase, P. aeruginosa ATCase is not inhibited competitively by PALA
(Fig. 7C, Table 3).
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Figure 7. Carbamoyl Phosphate and Aspartate Saturation Curves for P. aeruginosa
ATCase
Kinetics.
ATCase activity was measured described in Chapter 2. A) Carbamoyl phosphate
saturation: aspartate was fixed at 8 mM and carbamoyl phosphate was the variable
substrate. B) Aspartate saturation: carbamoyl phosphate fixed at 10 mM and aspartate
as the variable substrate. C) Carbamoyl phosphate saturation curves with aspartate fixed
at 8 mM, in the absence of PALA (○), and presence of 1 nM (●), 25 nM (■), 100 nM (□),
and 500 nM (♦) PALA. The saturation curves were fit to the Hill equation: v=Vmax[S]n/(Kmn
+ Sn).
Table 2: Steady State Kinetics of P. aeruginosa ATCase
Variable Substrate

Carbamoyl Phosphate

Aspartate (Asp)

(CP)
Km (mM)

2.8 ± 0.18

3.63 ± 0.41

Vmax (µmol/min/mg)

142 ± 7.5

183.2 ± 4.3

87.6

113.0

-1

kcat (s )
-1

-1

4

kcat/Km (s M )

3.1 X 10

Hill coefficient

2.82 ± 0.35

3.1 X 10

4

1.44 ± 0.14

Table 3: PALA Inhibition
PALA

Km

Vmax

Hill Coefficient

(nM)

(mM)

(µmol/min/mg)

0

1.27 ± 0.16

108.78 ± 6.60

1.46 ± .020

1

1.36 ± 0.12

110.73 ± 5.40

1.65 ± 0.20

25

1.74 ± 0.47

78.00 ± 10.72

1.40 ± 0.34

100

3.34 ± 0.24

70.73 ± 4.32

2.37 ± 0.24
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3.4.6 Circular Dichroism Spectroscopy of ATCase, pDHO, and the ATCase-pDHO
Complex
In the absence of pDHO, it is possible that the ATCase trimer does not form
because the protein is not folded properly. However, CD spectroscopy of isolated ATCase
and pDHO showed that both P. aeruginosa proteins have at least a well-defined
secondary structure (Fig. 8A, Table 4). The CD spectrum of ATCase-pDHO complex has
a similar secondary structure. More subtle changes in the tertiary structure no doubt
occur.
3.4.7 Thermal Stability of ATCase, pDHO, and ATCase-pDHO Complex
A thermal shift assay was employed to determine the relative stability of the
isolated subunits and the complex (Fig. 8B). The melting temperature of the proteins were
analyzed by calculating the first derivative of the fluorescence vs. temperature plot using
the Applied Biosystems 7500 software. ATCase and pDHO subunits had melting
temperatures of 38°C and 44°C, respectively. When the reconstituted ATCase-pDHO
complex was subjected to thermal shift, there was a dramatic positive shift in the melting
temperature of the complex to 77°C indicating that while the ATCase and pDHO subunits
are relatively unstable, the ATCase-pDHO dodecamer is quite stable.
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Figure 8: Folding and Thermal Stability of P. aeruginosa ATCase, pDHO and the
complex
A) The CD spectrum of P. aeruginosa ATCase, pDHO, and the ATCase-pDHO complex
formed by mixing stoichiometric amounts of the two subunits, in 5 mM sodium phosphate,
pH 8.0. B) The thermal stability of each purified recombinant protein, ATCase, pDHO,
and the ATCase-pDHO complex, was measured by preparing the proteins in buffer
containing 50 mM Tris pH 7.5 and 200 mM NaCl, and then subjecting the sample to a
thermal shift assay using 500X SYPRO Orange dye. The fluorescence was measured
over a temperature range of 25 °C to 95 °C.
Table 4: CD Spectroscopya
Secondary Structure

aThe

ATCase

pDHO

ATCase-pDHO

%

%

%

Helices

15.9

23.7

15.2

Sheets

32.3

26.4

33.4

Turns

22.0

21.7

22.3

Undetermined

29.8

28.2

26.6

average of two scans

3.4.8 Trimerization of P. aeruginosa ATCase
ATCase was subjected to size-exclusion chromatography on an S200 Superdex
column in the presence of 200 µM PALA in the sample as well as in the buffer, 50 mM
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Tris pH 7.5 and 200 mM NaCl. PALA is a bisubstrate analog that has a very high affinity
for the active site of ATCase. The active site of ATCase is composed of residues from
adjacent monomer. Therefore, the rationale for subjecting ATCase to size-exclusion in
the presence of PALA was that PALA would bind in the active site of the enzyme and
facilitate trimer formation. However, ATCase eluted as a monomer even in the presence
of PALA (Fig. 9A & B), indicating that PALA does not facilitate ATCase trimer formation.
Furthermore, ATCase was subjected to cross-linking with BS3 in the presence of 200 µM
PALA for up to two hours, however, most of the protein remained monomeric with some
trace of dimer formation (Fig. 9C & D).
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Figure 9: Trimerization of P. aeruginosa ATCase
A) The ATCase-pDHO preincubated with 200 μM PALA was analyzed by size-exclusion
chromatography on a Superdex S200 column. B) Size-exclusion eluted fractions were
analyzed on 12% SDS-PAGE; 1 and 2: fractions from the shoulder of the main peak, 37: fractions of the main peak. Purified ATCase was subjected to cross-linking with BS3
in the C) absence and D) presence of 200 μM PALA.
Additionally, a thermal shift assay was performed with ATCase and the ATCasepDHO complex in the presence and absence of PALA to determine the binding of PALA
to ATCase. No shift in melting temperature of ATCase was detected in the presence of
PALA. However, there was a 10 °C increase in the melting temperature of the ATCasepDHO complex in the presence of PALA suggesting that PALA only binds to ATCase
when ATCase is complexed with pDHO (Fig. 10).
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Figure 10: Thermal Stability of P. aeruginosa ATCase in the presence of PALA
The thermal stability of A) ATCase B) pDHO, and C) ATCase-pDHO complex, measured
in the presence and absence of PALA, using 500X SYPRO Orange dye. The fluorescence
was measured over a temperature range of 25 °C to 95 °C.
3.4.9 Activation of ATCase and Controlled Proteolysis by Elastase
The possibility was considered that there may be critical regions of the protein that
are intrinsically disordered. The Protein Disorder Prediction System (PrDOS) was
employed to identify possible disordered regions. This analysis predicted that the first 11
residues on the amino end and the last 13 residues on the carboxyl end are disordered.
These disordered regions are not present in the shorter E. coli ATCase polypeptide. The
inactivity of ATCase could be explained if the disordered extensions interfere with
ATCase trimer formation in the absence of the pDHO, a pre-requisite for the enzyme’s
activity. The pyrB gene of P. aeruginosa ATCase without the first 11 residues (delN
ATCase) and pyrB without the first 11 and last 13 residues (delNC ATCase) were cloned
into T7 pETite vector and purified as described for the native subunit. The overexpression
of mutant ATCases resulted in formation of insoluble inclusion bodies, therefore, mutant
ATCases could not be tested for activity in the absence of pDHO. However, when the
ATCase constructs were co- transformed and co-purified with pyrX gene encoding pDHO,
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the mutant ATCase-pDHO complex formed and was found to be active suggesting that
the truncation of the first 11 or last 13 residues did not affect the formation of ATCasepDHO complex or ATCase activity.
Furthermore, ATCase was subjected to controlled proteolysis by elastase. The
rationale for this experiment was that the elastase would cleave accessible and
disordered regions of the protein. If these regions exert any inhibitory constraints, the
ATCase may be activated. However, the time course of controlled proteolysis did not
induce recovery of the latent ATCase activity. The elastase proteolysis of ATCase was
also performed in the absence and presence of 200 µM PALA and pDHO to see if PALA
protects ATCase from proteolysis. PALA did not protect ATCase from elastase proteolysis
(Fig. 11A & B), whereas most of the ATCase was intact even after 120 minutes when it
was subjected to elastase proteolysis in the presence of pDHO (Fig. 11C).
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Figure 11: Controlled proteolysis of P. aeruginosa ATCase
Purified ATCase was subjected to proteolysis by elastase, A) in the absence of PALA or
pDHO B) in the presence of 200 μM PALA and C) in the presence of 200 μM PALA and
equimolar amount of pDHO. Samples were taken periodically over 60 minutes and
quenched by adding 5 µL of sample buffer consisting of 12 mM Tris-HCl, pH 6.8, 5%
glycerol, 0.4% SDS, 2.88 mM β-mercaptoethanol, and 0.02% bromophenol blue, and by
heating for 7 min at 100°C. The samples were analyzed by electrophoresis on SDS
12% polyacrylamide gel.
3.4.9 Nucleotide Inhibition
The ATCase-pDHO complex is strongly inhibited by nucleotide tri-phosphates (Fig.
12A). Carbamoyl phosphate saturation curves showed mixed inhibition, decreasing k cat,
and to a lesser extent increasing Km (Table 5). The most striking effect is a large increase
in the Hill coefficient as the ATP concentration increases. When the ATCase-pDHO
complex was cross-linked with BS3 in the presence of 10 mM ATP, (Fig. 12C) the
complex appeared to be less stable as indicated by the appearance of fewer and smaller
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intermediate species. Additionally, thermal shift data showed a negative 13°C shift of the
melting temperature of the ATCase-pDHO complex in the presence of ATP - a further
indication that ATP destabilizes the ATCase-pDHO complex (Fig. 12B). Additionally, the
ATCase-pDHO complex was subjected to size-exclusion chromatography on S200 in the
presence of 10 mM sodium pyrophosphate to determine complex dissociation. The
ATCase-pDHO complex eluted as a dodecamer in the presence of sodium
pyrophosphate indicating no dissociation (Fig. 12 E & F). Furthermore, the ATCasepDHO complex was preincubated with 10 mM ATP or sodium pyrophosphate and
analyzed on 7.5% native gel with 10 mM ATP or sodium pyrophosphate in the gel matrix
and gel running buffer. The ATCase-pDHO complex ran as a single band on native gel
indicating that the complex, although destabilized, is not completely dissociated by ATP
or sodium pyrophosphate (Fig. 12 D & G). Moreover, the mutations in ATCase, delN or
delNC, did not affect ATP inhibition suggesting that the ATP binding site is not present
within the first 11 residues of N terminal as previously suggested.
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Figure 12: Nucleotide Inhibition
A) The ATCase activity of the ATCase-pDHO complex was measured with carbamoyl
phosphate as the variable substrate, aspartate fixed at 8 mM in the absence of ATP (○)
and in the presence of 0.5 mM (●), 1 mM (□), 2.5 mM (■), 5 mM (▲), and 10 mM (Δ) ATP.
B) Preformed ATCase-pDHO complex prepared in buffer containing 50 mM Tris pH 7.5
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and 200 mM NaCl was subjected to thermal shift assay using 500X SYPRO Orange dye,
in the presence and absence of 10 mM ATP. The fluorescence was measured over a
temperature range of 25 °C to 95 °C. C) Purified recombinant ATCase (36 µM) and pDHO
(37 µM) in 50mM sodium phosphate, pH 7.5, and 500 mM NaCl, were cross-linked for
the indicated times with 5 mM bis(sulfosuccinimidyl)suberate in the absence and
presence of 10 mM ATP. D) Gel-filtered ATCase, pDHO, and the ATC-pDHO complex
were preincubated with 10 mM ATP and subjected to native gel electrophoresis with 10
mM ATP in the gel matrix and running buffer. E) Purified recombinant equimolar ATCase
and pDHO were subjected to size-exclusion chromatography on Superdex S200 column
in the presence of 10 mM sodium pyrophosphate and F) the fractions corresponding to
the peak were analyzed on 12% SDS-PAGE. G) Gel-filtered ATCase, pDHO, and the
ATC-pDHO complex were preincubated with 10 mM sodium pyrophosphate and
subjected to native gel electrophoresis with 10 mM sodium pyrophosphate in the gel
matrix and running buffer.
Table 5: ATP Inhibition of P. aeruginosa ATCase
ATP

Vmax

Km

nH

mM

µmol/min/mg

mM

0

289 ± 5.0

0.88 ± 0.03

2.4

0.5

300 ± 10

1.22 ± 0.07

3.2

1.0

247 ± 2.7

1.62 ± 0.02

3.8

2.5

164 ± 2.6

2.83 ± 0.32

14.7

5

96.6 ± 1.1

3.53 ± 0.10

12.7

10

29.1 ± 2.7

2.76 ± 0.48

10.3

3.4.10 Structure of P. aeruginosa delN ATCase-pDHO Complex
The crystal structure of P. aeruginosa delN ATCase-pDHO complex at 2.47 Å has
been refined to a final Rwork value of 28% and a Rfree value of 33%. The crystal structure
belongs to space group H32 with unit cell parameters a = b = 171.65, c = 159.53 Å. The
crystal structure contains a heterodimer of one delN ATCase, one pDHO, and two TEW
molecules in its crystallographic asymmetric unit (Fig. 13A).
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The P. aeruginosa delN ATCase chain has an overall fold like the other known
ATCases with carbamoyl phosphate (residues 1-149) and aspartate (residues 166-298)
domains connected by a hinge region (residues 150-165, 299-323). delN ATCase chain
lacks continuity of electron density at 1.0 σ for the main chain of residues 45-49, 56-57,
92-99, 212, 242-251, and 272-273. Superimposition of A. aeolicus ATCase and P.
aeruginosa ATCase gave an RMSD (root mean square deviation) of 1.75 Å for 283 Cα
atoms. Saturating concentration of 200 μM PALA was added to the delN ATCase-pDHO
solution prior to crystallization yet density for PALA was not found in the active site.
Instead unambiguous density for TEW ([TeW6O24]6−) was present in the active site (Fig.
13C). TEW is a tellurium-centered Anderson-Evans polyoxotungstate that was present
as an additive in the crystallization solution. This highly charged molecule with a total net
charge of -6 interacts with positively charged regions of the protein and is known to
stabilize flexible regions while maintaining the integrity of the protein [125]. TEW interacts
covalently and through hydrogen bond interactions with the residues in the ATCase active
site (Fig. 13D). TEW interacts through hydrogen bonding with a number of residues in the
active site of ATCase including Ser 68, Arg 70, Arg 120, Arg 239 and Glu 243, but most
importantly, TEW also interacts with residues of the 90’s loop from the adjacent monomer
including Ser 95 and Ser 97, thus stabilizing the active site and delN ATCase trimer. PALA
has a very high affinity for the active site of ATCases – e.g. a Ki of 27 nM for E. coli
ATCase [126]. The displacement of PALA by TEW in the active site of P. aeruginosa delN
ATCase implies that TEW has a higher affinity for delN ATCase than PALA and that TEW
may have an inhibitory role on P. aeruginosa delN ATCase.
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P. aeruginosa pDHO chain folds into a TIM barrel domain (residues 56-365)
connected to β-stranded adjacent domain (residues 1-55, 366-423) like other known
DHOases. The pDHO chain lacks continuity of electron density for the main chain of
residues 34-42. Superimposition of A. aeolicus DHOase and P. aeruginosa pDHO gave
an RMSD of 1.38 Å for 420 Cα atoms. The second TEW molecule in the asymmetric unit
was found to interact with pDHO through hydrogen bonding with Arg 71 and Arg 97.

Figure 13: Crystal Structure of P. aeruginosa delN ATCase and pDHO
A) The single molecule of P. aeruginosa delN ATCase and pDHO with two molecules of
TEW in the asymmetric unit. CP and Asp domains and hinge region of ATCase are

46

colored in red, green, and blue, respectively. TIM-barrel and β-stranded domains of pDHO
are colored in yellow and orange respectively, whereas pDHO loop A is colored in purple,
loop B in cyan, and loop C in white. B) Hydrogen bond interactions between pDHO loop
A (magenta) and the interdomain cleft of delN ATCase. C) Electron density map of TEW
in the active site of delN ATCase. D) MOE ligand interaction map of TEW with the delN
ATCase active site residues of chain A and chain B.
The unit cell of this crystal space group contains 18 copies of the heterodimer delN
ATCase and pDHO. The Protein Interfaces, Surfaces, and Assemblies service (PISA)
[119] at the European Bioinformatics Institute identified a dodecameric assembly of delN
ATCase and pDHO based on the largest buried surface area and the largest numbers of
stabilizing interactions. Each delN ATCase subunit interacts with five other chains
including two delN ATCases in the same trimer (A2 and A3) and three pDHO (D1, D4,
and D2) in the central torus. In A. aeolicus, loop A at the top of the TIM barrel of DHOase
plays an important role as 12 residues from this loop contribute to the interface with
ATCase [15, 39]. A. aeolicus ATCase interacts with DHOase through 9 hydrogen bond
interactions and 7 salt bridges. In P. aeruginosa, pDHO loop A also interacts with residues
in the delN ATCase interdomain cleft. However, in P. aeruginosa, only three hydrogen
bond interactions were found between pDHO loop A (D1) and ATCase (A1). Loop A Ser
199 interacts with ATCase Arg 186 and loop A Gly 202 interacts with ATCase Arg 147.
ATCase also interacts with another chain of pDHO (D4) through ATCase Arg 206 – pDHO
Thr 172 , ATCase Glu255 – pDHO Glu138, and ATCase Thr207 – pDHO Glu168. Lastly,
ATCase interacts with pDHO D4 through hydrogen bond between ATCase Gly 285 –
pDHO Arg 71. Each pDHO chain interacts with three other chains; its delN ATCase
partner (A1) and two other pDHO chains (D4 and D5) in the opposite trimer. All chain
interactions calculated by PISA [119] are depicted in Fig. 14 and listed in Table 6.
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Figure 14: The dodecamer of P. aeruginosa ATCase and pDHO
A schematic diagram showing the interfaces listed in Table 6, A) the delN ATCase trimer,
B) the pDHO hexamer, and C) the dodecamer. The delN ATCase (purple) and pDHO
(yellow), D) top view with three ATCase chains labelled A1-A3 and three pDHO chains
attached to the top trimer are labelled D1-D3, H) sideview of the dodecamer rotated 90
degrees horizontally.
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Table 6: Chain Interfaces Calculated by PISA
Interface Chain1:Chain 2 Residues

Buried

H-

Salt

Area

bonds

bonds

CSSa

Color

1

pDHO1:pDHO4

27:26

1051

18

12

0.148

Green

2

ATC1:ATC2

24:26

889

9

1

0.307

Cyan

(2)

ATC1:ATC3

24:26

889

9

1

0.307

Blue

3

ATC1:pDHO1

28:24

790

3

0

0.287

Red

4

ATC1:pDHO4

14:18

543

2

0

0.176

Orange

5

pDHO1:pDHO5

12:12

365

2

4

0.037

Yellow

6

ATC3:pDHO1

6:3

124

1

0

0.011

Purple

aComplexation

significance score

With successful crystallization of P. aeruginosa delN ATCase trimer as a part of
the dodecamer, P. aeruginosa delN ATCase monomer-monomer ATCase interactions
were analyzed using the protein interfaces service from PISA [119] and compared with
E.coli (PDB: 1Q95), Bacillus subtilis (PDB: 3R7D), S. aureus, A. aeolicus (PDB: 3D6N),
and human ATCase (PDB: 5G1N). Although ΔiG or the free energy of solvation and the
buried surface area upon interface formation were not very different, the number of salt
bonds and hydrogen bonds was significantly lower for P. aeruginosa delN ATCase
compared to all other ATCases as shown in Table 7. This suggests that although the
hydrophobic interactions might be conserved, P. aeruginosa ATCase has very few
electrostatic interactions at the monomer-monomer interface and most likely the reason
why it is a monomer in solution in the absence of pDHO.
Table 7: Monomer-Monomer Interface Interactions
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ATCase

# H-bonds

# Salt bonds

Buried Area

ΔiG (kcal/mol)

2

E. coli

16

12

(Å )
1058.8

B. subtilis

14

9

941.0

-6.4

S. aureus

19

8

1089.3

-10.2

A. aeolicus

19

8

958.9

-5.5

H. sapiens

18

17

1075.6

-7.7

P. aeruginosa

9

1

889.4

-4.1

-7.6

3.4.11 Inhibition of P. aeruginosa ATCase by TEW
Due to the displacement of PALA by TEW from the active site of P. aeruginosa
ATCase during the crystallization process, ATCase assay was performed to assess the
effect of TEW on P. aeruginosa ATCase activity. TEW inhibited P. aeruginosa ATCase
with an IC50 in the range of 0.1 – 1 μM (Fig. 15). The assay will have to be repeated to
determine a more accurate IC50 value, nonetheless, TEW is a potent inhibitor of P.
aeruginosa ATCase.
W
Te

TEW
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Figure 15. IC50 of TEW against P. aeruginosa ATCase
P. aeruginosa ATCase assay was performed with 2.5 mM carbamoyl phosphate, 2 mM
aspartate, and increasing concentrations of TEW.
3.5 Discussion
Previous studies have shown that Pseudomonas ATCases have some unusual
properties. All ATCase catalytic subunits from bacteria, fungi, and plants [127-129] have
homologous sequences, have the same catalytic residues and mechanism and form
stable catalytically active trimers. Although Schurr et al. [20] did not isolate the ATCase
subunit they showed the ATCase activity in Pseudomonas putida was dependent on the
presence of the pDHO domain and correctly concluded that it was necessary for the
stability of the ATCase-pDHO complex. In this study we have cloned and expressed both
the P. aeruginosa inactive ATCase and pDHO subunits and found that a relatively stable
dodecameric complex with full ATCase activity could be reconstituted when the two
subunits were mixed in a 1:1 stoichiometric molar ratio.
Unlike all other ATCase that have been previously studied, the ATCase chains
from these Pseudomonas species are monomeric and do not assemble into a catalytically
active trimer unless the pDHO subunit is present. No significant amount of the ATCase
trimer could be detected by size-exclusion chromatography or by chemical crosslinking.
In contrast, chromatography indicated that the pDHO subunit formed a stable dimer,
although the dimer did not crosslink because there are no appropriately positioned lysine
residues at the dimer interface as known from the crystal structure of P. aeruginosa delN
ATCase-pDHO dodecamer. The failure to form a stable ATCase trimer accounts for its
lack of catalytic activity since the active site of every known ATCase requires a conserved
serine and lysine (Ser80 and Lys840 in E. coli) from the adjacent subunit that participates
in catalysis.
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The three very important interactions between E. coli ATCase monomers in the
catalytic trimer have been identified to be Lys-41, Asp-100, and Asp-90 of one monomer
that form salt links with Glu-37, Arg-65, and Arg-269 of the adjacent subunit [130, 131].
Multiple sequence alignment of P. aeruginosa ATCase with other trimeric ATCases (Fig.
16) showed that two of the three interactions are partially conserved in P. aeruginosa.
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Ec
Hs
Aa
Pa
Sa

1Q95_C
5G1P_D
3D6N_B
AAA25976.1
BAF78073.1

1Q95_C
5G1P_D
3D6N_B
AAA25976.1
BAF78073.1

-----------ANPLYQKHIISINDLSRDDLNLVLATAAKL-----KANPQPELLKHKVI 44
---GPMS--PLLHSLVGQHILSVQQFTKDQMSHLFNVAHTLRM-MVQKERSLDILKGKVM 54
----------------MRSLISSLDLTREEVEEILKYAKEFKEGKEETIKA-------SA 37
MPTDAKRPLQLNDQGQLRHFISLDGLPRELLTEILDTADSFLEVGARAVKKVPLLRGKTV 60
----------------MNHLLSMEHLSTDQIYKLIQKASQFK----SGERQLPNFEGKYV 40
. ::*
: : : :: * :
ASCFFEASTRTRLSFETSMHRLGASVVGFSDSANTSLGKKGETLADTISVIST-YVDAIV 103
ASMFYEVSTRTSSSFAAAMARLGGAVLSFSEAT--SSVQKGESLADSVQTMSC-YADVVV 111
VLFFSEPSTRTRLSFEKAARELGIETYLVSGSE--SSTVKGESFFDTLKTFEGLGFDYVV 95
CNVFFENSTRTRTTFELAAQRLSADVISLNVST--SSTSKGETLTDTLRNLEAMAADMFV 118
ANLFFENSTRTKCSFEMAELKLGLKTISFETST--SSVSKGESLYDTCKTLESIGCDLLV 98
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***:: *:
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* .*

H5
1Q95_C
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AAA25976.1
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FRVPFVFF-PYKEIVKSLNLRLVNAGDGTHQHPSQGLIDFFTIKEHFGEVKDLRVLYVGD 154
VRHSDSGAAHFIAEHVSPNVAVINGGDGRHAHPTQGMLDMLTIRRHKGNFEQLSVAIVGD 178
IRHPFNN---YYEKLANINIPIANAGDGSGQHPTQSLLDLMTIYEEYGYFEGLNVLICGD 155
.*
. : *.***
**:* ::*::** . * .. : :
**

1Q95_C
5G1P_D
3D6N_B
AAA25976.1
BAF78073.1
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LKHGRTVHSLACLLTQYRVS-LRYVAPPSLRMPPTVRAFVASRGTKQEEFESIEEALPDT 228
IKHSRVFRSGAPLLNMFGAKI-GVCGPKTLI-P-----RDVE-VFKVDVFDDVDKGIDWA 206
ILHSRVARSNMLALKTLGCPDIRVIAPATLL-P-----IGLEEQYGVRVFTNADEGLKDV 232
IKNSRVARSNYHSLKALGANVMF-NSPNAWI-D-----DSLE-----APYVNIDDVIETV 203
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1Q95_C
5G1P_D
3D6N_B
AAA25976.1
BAF78073.1

DILYMTRVQKERLDP-SEYAN----VKAQFVLRASDLHNAKANMKVLHPLP--RVDEIAT 275
DVLYMTRIQKERFGSTQEYEA----CFGQFILTPHIMTRAKKKMVVMHPMP--RVNEISV 282
DVVIWLRLQKERQKE--NYIPSESSYFKQFGLTKERFEKV---KLYMHPGPVNRNVDIDH 261
DVVIMLRLQRERMQG--GLLPSEGEFFKLYGLTEKRLKLAKPDAIVMHPGPINRGVEIES 290
DIVMLLRIQHERHGLAEETRFAADDYHQKHGLNEVRYNKLQEHAIVMHPAPVNRGVEIQS 263
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H12

1Q95_C
5G1P_D
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AAA25976.1
BAF78073.1

DVDKTPHAWYFQQAGNGIFARQALLALVLNRDLVL--------EVDSDPRAAYFRQAENGMYIRMALLATVLGRF-----------ELVYTEKSLIQEQVKNGIPVRKAIYKFLWT-------------AVADGAQSVILNQVTYGIAIRMAVLSMAMSGQNTQRQLEQEDAE
DLVEASKSRIFKQMENGVYLRMAVIDELLK-------------:
::
.*
*: * *:

310
314
291
334
293

Figure 16: Sequence Similarity of ATCases
A CLUSTAL O (1.2.4) multiple sequence alignment of ATCase catalytic chain or domain
of ATCase from E. coli (Ec), Homo sapiens (Hs), Aquifex aeolicus (Aa), Pseudomonas
aeruginosa (Pa) and Staphylococcus aureus (Sa). Active site residues are highlighted in
red; H5 and H12 represent the residues that connect the carbamoyl phosphate and
aspartate domains of ATCase; residues involved in monomer-monomer interactions are
boxed in red; amino and carboxyl end extensions of P. aeruginosa ATCase are
highlighted in green.
CD analysis showed that both the isolated subunits can spontaneously assume a
typical secondary structure, although neither ATCase nor pDHO is very stable with
melting temperatures as determined by the thermal shift assay were 38°C and 44°C
respectively. Formation of the complex appreciably stabilizes the protein, raising the
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melting temperature to 77°C. Time-dependent chemical crosslinking of the reconstituted
dodecamer of the A. aeolicus ATCase-DHOase complex showed a progressive
disappearance of the monomers and the formation of the 240 kDa hexamer which
gradually disappears with the formation of the 480 kDa dodecamer. In contrast,
crosslinking of preformed P. aeruginosa ATCase-pDHO gave a complex but highly
reproducible pattern of 8 bands, that gradually gave way to species of higher molecular
mass. This pattern may have resulted from the intrinsic instability of the subunits and the
lack of pDHO crosslinking.
As reported previously [123] micromolar levels of nucleotide tri- and di-phosphates
competitively inhibit P. fluorescens when carbamoyl phosphate is limiting (7.5-30 µM). At
higher carbamoyl phosphate concentrations (10 mM), nucleotides are non-competitive
inhibitors [132]. The regulatory logic of these phenomena is elusive. E. coli ATCase is
allosterically inhibited by UTP and CTP and activated by ATP. The rationale is that this
regulatory mechanism provides a balance between the synthesis of pyrimidines and
purines. However, P. aeruginosa ATCase is inhibited by both pyrimidines and purines.
The inhibitors tend to shift the saturation curve to higher substrate concentrations and
increase cooperative substrate binding and Hill coefficient. The Monod, Wyman and
Changeux model stipulates that the upper limit of the Hill coefficient equals the number
of substrate binding sites. The Hill coefficients for P. aeruginosa ATCase here and in a
previous study [21] far exceed the number of effector binding sites suggesting that the
observed sigmoidicity does not reflect true homotropic or cooperative substrate binding.
The ATP binding site was previously shown to be located on the ATCase catalytic subunit
by affinity labeling with the radiolabeled ATP analog, [ 3H]-FSBA. Previous studies [124]
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provided evidence that ATP binds to the 11 residue extension on the amino end of the
catalytic polypeptide. However, subcloning of deletion mutants lacking the extension on
the amino end and the carboxyl ends of the protein were inhibited by ATP. We conclude
that the nucleotide inhibition is a consequence of the nucleotide induced destabilization
of the ATCase-pDHO complex and does not represent an allosteric regulatory
mechanism. How then is pyrimidine biosynthesis regulated in P. aeruginosa? A possible
explanation is that carbamoyl phosphate synthetase (CPSase) which provides the
ATCase substrate, carbamoyl phosphate, regulates ATCase. P. aeruginosa CPSase. Is
controlled by metabolites in the arginine biosynthetic pathway but is also feedback
inhibited by CTP [133].
The crystallization of P. aeruginosa delN ATCase-pDHO in space group H32
revealed one delN ATCase, one pDHO, and two TEW in the asymmetric unit. The
biological assembly of P. aeruginosa subunits is a dodecamer consisting of six copies of
both subunits as shown by size-exclusion and cross-linking experiments. Crystallization
of delN ATCase-pDHO in the presence of TEW resulted in displacement of PALA and
binding of TEW to the active site of delN ATCase. TEW interacts through hydrogen
bonding with the active site residues of the main chain as well as 90’s loop from the
adjacent monomer suggesting that TEW stabilizes the delN ATCase trimer. TEW was
found to be a potent inhibitor of P. aeruginosa ATCase with an IC50 value in the low
micromolar range.
In summary, although the isolated ATCase from P. aeruginosa has a well-defined
secondary structure, it is relatively unstable and does not self-associate to form a stable
trimer. Association with the pDHO subunit is therefore necessary to stabilize the
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catalytically active timer and to form the dodecamer. ATP induced destabilization of the
ATCase-pDHO complex accounts for the inactivation of the ATCase catalytic subunit.
3.6 Future Directions
It is important to obtain the crystal structure of P. aeruginosa ATCase and pDHO
in the absence of TEW to determine if TEW led to distortion of DAC in any way. The
inhibitory effect of TEW on P. aeruginosa ATCase should be explored more thoroughly.
Experiments to be performed:
•

Crystallization of apo ATCase-pDHO complex

•

Co-crystallization of ATCase-pDHO complex in the presence of ATP to determine
ATP binding site

•

P. aeruginosa and A. aeolicus ATCase activity assay in the presence of TEW

•

Crystallization of P. aeruginosa and A. aeolicus ATCase in presence of TEW

•

Crystallization of A. aeolicus ATCase-DHOase (DAC) in the presence of TEW
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CHAPTER 4: ASPARTATE TRANACARBAMOYLASE IN STAPHYLOCOCCUS
AUREUS
4.1 Abstract
Staphylococcus aureus is a commensal pathogen that has become a serious
threat due to its emerging multi-drug resistance, especially to methicillin and vancomycin.
The aspartate transcarbamoylase (ATCase) of this organism is a trimer comprised of
three 33 kDa catalytic chains. We have cloned the pyrB gene of S. aureus encoding
ATCase, overexpressed the clone in E. coli and purified the protein using nickel affinity
chromatography. Chemical cross-linking and size-exclusion chromatography showed that
ATCase is a 99 kDa homotrimer. The carbamoyl phosphate saturation curve of ATCase
is hyperbolic whereas the aspartate saturation curve is sigmoidal. Furthermore, the
ATCase activity was inhibited by mM amounts of ATP with a decrease in V max and slight
change in the Km indicating non-competitive inhibition of ATCase. Moreover, crosslinking, size-exclusion, and enzyme activity assays showed no evidence of interaction of
ATCase with dihydroorotase (DHOase), the third enzyme in the pathway, which often
forms a complex with ATCase. This study also presents the three-dimensional structure
of S. aureus ATCase bound to PALA, N-phosphonacetyl-L-aspartate, a bi-substrate
inhibitor of the enzyme. The X-ray structure of S. aureus ATCase closely resembles the
Bacillus subtilis homotrimeric ATCase.
4.2 Introduction
Staphylococcus belongs to Micrococcaceae family of eubacteria that naturally
colonizes the human skin. Staphylococcus aureus is a leading cause of health-care
associated and community-associated infections in immunocompromised individuals.
There is an increased morbidity and mortality associated with S. aureus infection when it
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manifests into bacteremia, infective endocarditis, metastatic infection, and/or sepsis [134,
135]. Emerging resistance of S. aureus to methicillin and vancomycin poses an urgent
need for the development of new antimicrobial drugs. In the design of therapeutic
strategies, pyrimidine metabolism of this organism has not been thoroughly
explored.
Aspartate transcarbamoylase (ATCase; EC 2.1.3.2) catalyzes the reaction of
carbamoyl phosphate (CP) and aspartate to form N-carbamoyl-l-aspartate (CA) and
inorganic phosphate [7] a key step in de novo pyrimidine biosynthesis. ATCase catalyzes
the same reaction in all organisms but is highly polymorphic. In mammals, the first three
enzymes of the pyrimidine biosynthesis are consolidated on a single polypeptide, called
CAD,

combining

carbamoyl

phosphate

synthetase

(CPSase),

aspartate

transcarbamoylase, and dihydroorotase (DHOase) [136]. The 243 kDa CAD then selfassociates into a hexamers and higher oligomers [137] exceeding a molecular mass of
1.4 MDa [2].
We report here the overexpression, purification, and crystallization of S. aureus
ATCase. We have also determined the oligomeric state of the protein, the kinetic
properties, and whether it associates with DHOase. S. aureus is a 99 kDa trimer of
catalytic chains and it does not associate with DHOase. The X-ray structure of S. aureus
ATCase shares a high sequence similarity with B. subtilis ATCase and both ATCases
have a very similar tertiary structure. S. aureus ATCase was found to be inhibited by
nucleotides indicating allosteric regulation.
4.3 Materials and Methods
4.3.1 Crystallization, Data Collection, and Structure Refinement
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Gel-filtered ATCase in 50 mM Tris-HCl, pH 7.5, 200 mM NaCl, and 1 mM
dithiothreitol was concentrated in the Amicon Ultra-15 centrifugal filter units (EMD
Millipore) to a final concentration of 8.85 mg/mL as determined by the Lowry method [29]
using bovine albumin serum as a standard. Prior to crystallization, N-phosphonacetyl-Laspartate or PALA was added to protein at a final concentration of 200 µM. All crystals
were grown at room temperature using the sitting-drop, vapor diffusion method. PALAbound ATCase crystals were grown by mixing 1 µL of ATCase-PALA and 1 µL of 2 M
ammonium sulfate, 5% polyethylene glycol 400, and 0.1 M sodium 2-(N-Morpholino)
ethanesulfonic acid or MES, pH 6.5. Crystals that grew within 10 days were then used for
preparing seed stock for performing subsequent seeding experiment. A 2 µL drop
solution, including the crystals, was added to 50 µL of reservoir solution into the
microcentrifuge tube with the Seed Bead (Hampton), which was then vortexed for 3
minutes, and used as seed stock. One µL of 1:4 diluted seed stock was mixed with 1 µL
of 8.85 mg/mL ATCase to allow crystal growth at room temperature. The best diffracting
cubic crystals grew to 0.1 mm x 0.1 mm within 2-4 days. The crystals were soaked in a
cryoprotectant solution consisting of mother liquor and 20% ethylene glycol prior to
freezing in liquid nitrogen. X-ray diffraction data were collected at Advanced Photon
Source, Argonne National Laboratory in Illinois. The crystals belong to the space group
P3221 and diffracted to 2.27 Å resolution, with three ATCase molecules in the asymmetric
unit. The structure was solved by the molecular replacement method with the program
PHASER within the Phenix suite [114] using crystal structure of unliganded ATCase from
Bacillus subtilis, PDB: 3R7D, [26] as the search model. Structure modeling was carried
out in COOT [115] and refinement was performed using Phenix and PDB-Redo [116].

59

4.4 Results
4.4.1 Expression and Purification of S. aureus ATCase and DHOase
The pyrB gene encoding S. aureus ATCase and pyrC gene encoding DHOase was
cloned into pmcsg19c vector incorporating a 6x his-tag on the amino terminus of the
protein. The resulting constructs was transformed into E. coli Hi-Control BL21(DE3) cells.
The proteins were expressed and purified using Ni2+ affinity chromatography as described
in chapter 2. ATCase and DHOase were soluble and expressed at 50 mg/liter of culture
(Fig. 17A & B).

Figure 17: Expression and Purification of S. aureus ATCase and DHOase
The pyrB gene encoding S. aureus ATCase pmcsg19c was cloned into the expression
vector that incorporates a 6xHis tag on the amino end of the recombinant proteins. The
resulting constructs were transformed separately into E. coli Hi-Control BL21(DE3) cells
(Lucigen). The transformants were grown at 37°C in LB medium until OD600 of 0.6 and
induced with 0.1 mM IPTG overnight (16-18 hours) at 20°C. The cells were harvested
and resuspended in 50 mM sodium phosphate and 0.5 M NaCl, pH 7.5, and lysed by
sonicating and French pressing once. The cell lysate was centrifuged at 12,000 x g for 45
minutes at 4°C. The supernatant was applied to 5.0-ml Ni2+ affinity column. The column
was washed with 10 column volumes with increasing concentration of imidazole up to
100 mM. the proteins were eluted in 5-ml aliquots with 250 mM imidazole in the same
buffer. The fractions were analyzed by electrophoresis on 12% SDS-PAGE Laemmeli
gels, A) ATCase and B) DHOase.
4.4.2 Oligomeric Structure of ATCase and DHOase
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On SDS-PAGE, under denaturing conditions, ATCase had an estimated molecular
mass of 33 kDa, in agreement with that calculated mass from the amino acid sequence.
Nickel column purified ATCase was then subjected to gel filtration chromatography on a
calibrated Superdex S200 column. ATCase eluted as a single species with a molecular
mass of 99 kDa indicating that it is a trimer under non-denaturing conditions (Fig. 18A &
B).

This

result

was

confirmed

by

chemical

cross-linking

with

BS3

(bis(sulfosuccinimidyl)suberate). The time course of the cross-linking reaction of ATCase
showed a gradual formation of ATCase dimer and then trimer with disappearance of the
monomeric species (Fig. 18E).
DHOase had an estimated molecular weight of 45 kDa but eluted as a single
species with a molecular weight of 90 kDa indicating that DHOase is a dimer in solution
(Fig. 18C & D). Upon cross-linking DHOase with BS3, there is a gradual increase in
dimeric species and a decrease in monomeric species when analyzed on 4-20% gradient
SDS-PAGE (Fig. 18F).
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Figure 18: Oligomeric Structure of S. aureus ATCase and DHOase
A) Purified S. aureus ATCase was subjected to size-exclusion chromatography on a
Superdex S200 Akta column and B) fractions 17 and 18 corresponding to the ATCase
peak were analyzed by 12% SDS-PAGE. C) Purified S. aureus DHOase was subjected
to size-exclusion chromatography on a Superdex S200 Akta column and D) fractions 17
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and 18 corresponding to the DHOase peak were analyzed by 12% SDS-PAGE. E)
Purified recombinant ATCase (45 μM) and F) DHOase (45 μM) in 50mM sodium
phosphate, pH 7.5, and 500 mM NaCl, were cross-liked for the indicated times with 5 mM
bis(sulfosuccinimidyl)suberate. The reaction was quenched by adding 10 ul of 1M TrisHCl, pH 8. Cross-linked species were analyzed by electrophoresis on 4-15% gel.
4.4.3 ATCase Steady State Kinetics
The steady state kinetics parameters were obtained from carbamoyl phosphate
and aspartate saturation curves of ATCase. The carbamoyl phosphate curve of ATCase
was hyperbolic (Fig. 19A). A least square fit of the Michaelis-Menten equation gave a Km
for carbamoyl phosphate ([S]0.5) of 2.4 mM and a Vmax of 305 µmoL/min/mg (Table 8).
The aspartate saturation curve of ATCase was sigmoidal and indicated cooperative
substrate binding with a Km for aspartate ([S]0.5) of 4.5 mM and a Vmax of 287
µmoL/min/mg with a Hill-coefficient of 2 (Fig.19B, Table 8). The bi-substrate inhibitor Nphosphonacetyl-L-aspartate designed to resemble the E. coli ATCase transition state is
also a potent inhibitor of S. aureus ATCase (data not shown).

Figure 19: Steady State Kinetics of S. aureus ATCase
The ATCase activity was measured as described in chapter 2, A) aspartate fixed at 8 mM
and carbamoyl phosphate as the variable substrate. The carbamoyl phosphate saturation
curve was fit to the Michaelis-Menten equation, v=Vmax [S]/([S] + Km). B) carbamoyl
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phosphate fixed at 5 mM and aspartate as the variable substrate.
saturation curve was fit to the Hill equation: v=Vmax[S]n/(Kmn + Sn).

The aspartate

Table 8: Steady State Kinetics of S. aureus ATCase
Variable Substrate

Carbamoyl Phosphate

Aspartate (Asp)

(CP)
Km (mM)
Vmax (µmol/min/mg)
-1

kcat (s )
-1

-1

2.42 ± 0.41

4.57 ± 0.35

305.73 ± 19.07

287.11 ± 16.81

168.15

157.91

kcat/Km (s M )

6.9 X 10

Hill coefficient

-

4

3.4 X 10

4

2.00 ± 0.16

4.4.4 Nucleotide Inhibition
S. aureus ATCase was found to be inhibited by ATP (Fig. 20). ATCase activity was
measured by keeping aspartate constant, varying carbamoyl phosphate concentration,
and increasing ATP concentration up to 10 mM. Carbamoyl phosphate saturation curves
indicated non-competitive inhibition decreasing Vmax with a little change in Km up to 10
mM ATP (Table 9). At 10 mM ATP, the increase in Km may indicate that the ATP might
be starting to occupy the active site.
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Figure 20: ATP Inhibition of S. aureus ATCase
The ATCase activity was measured with carbamoyl phosphate as the variable substrate,
aspartate fixed at 8 mM in the absence of ATP (●) and in the presence of 1 mM (○), 2.5
mM (■), 5 mM (□), 5 mM (♦), and 10 mM (▲) ATP.
Table 9: ATP Inhibition
ATP

Vmax

Km

mM

µmol/min/mg

mM

0

305.7 ± 19.0

2.42 ± 0.41

1.0

235.04 ± 18.3

1.93 ± 0.44

2.5

180.24 ± 13.6

1.99 ± 0.44

5

92.8 ± 13.3

2.29 ± 0.92

10

81.8 ± 9.3

6.72 ± 1.44

4.4.5 Association of Dihydroorotase
To examine whether S. aureus ATCase associates with dihydroorotase (DHOase),
nickel column purified recombinant ATCase and DHOase proteins were mixed in a 1:1
ratio and rotated overnight in 4°C. This mixture was then subjected to size-exclusion
chromatography on Superdex S200 column. ATCase and DHOase did not form a
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complex as evidenced by elution of both proteins in a single peak comprised of both the
ATCase trimer (99 kDa) and DHOase dimer (90 kDa) (Fig. 21A & B). Furthermore, an
equimolar ratio of ATCase and DHOase mix was subjected to cross-linking with BS3. The
monomeric ATCase and DHOase bands gradually decreased leading to a large band
around 100 kDa possibly a mixture consisting of ATCase trimer and DHOase dimer (Fig.
21C). No complex formation was observed due to the absence of higher molecular weight
species on the cross-linking gel. Under the assumption that ATCase and DHOase form a
very transient complex unable to detect, we assessed the ATCase activity in the presence
and absence of DHOase. However, there was no change in the activity of ATCase in the
presence of DHOase suggesting that ATCase and DHOase do not interact (Fig. 21D &
E).
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Figure 21: Association of S. aureus ATCase with DHOase
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A) Purified S. aureus ATCase and DHOase were mixed in an equimolar ratio and
subjected to size-exclusion chromatography on a Superdex S200 Akta column and B)
fractions 16, 17, and 18 corresponding to the peak were analyzed by 12% SDS-PAGE.
C) Recombinant ATCase (45 μM) and DHOase (45 μM) were cross-linked for the
indicated times with 5 mM bis(sulfosuccinimidyl)suberate. The cross-linked species were
analyzed on 12% SDS-PAGE. D) DHOase activity was measured in the (■) presence and
(○) absence of ATCase, E) ATCase activity was measured in the (■) presence and (○)
absence of DHOase.
Table 10: Kinetics of ATCase and DHOase Association
Variable
Substrate

Dihydroorotate

Dihydroorotate

1.55

Carbamoyl
Aspartate
Without
DHOase
0.99

Without ATCase

With ATCase

Km (mM)

1.36

Vmax
(µmol/min/mg)
Hill coefficient

Carbamoyl
Aspartate
With DHOase
1

3.2

3.5

23.27

23.79

-

-

0.99

1

4.4.6 Structure Analysis
The overall topology of the S. aureus ATCase-PALA is like the c3 units of B. subtilis
and E. coli. ATCase has an equilateral triangular appearance with three-bladed propeller,
mushroom-shaped cap facing the top face, a stalk-like central cavity, and active sites at
the bottom face (Fig. 22A & B). PALA liganded ATCase crystal type belong to space
group P3221 with unit cell parameters a = b = 113.33, c = 151.33 Å.
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Figure 22: General Schematic of ATCase Structure
Perpendicular views of ATCase with A) top face of ATCase, B) stalk-like central cavity
and active sites at the bottom face.
The structure of saATCase-PALA crystals at 2.27 Å resolution has been refined to
a final Rwork of 21% and Rfree of 23%. The crystal structure contains one trimer in the
asymmetric unit, where a molecule of PALA was observed in the active site of every
subunit (Fig. 23A). The RMSD between Cα atoms for 293 residues between chains A:B
is 0.10 Å, chains A:C is 0.12 Å, and chains B:C is 0.11 Å. The volume of the ATCase
active site was calculated using CASTp [138]. Because B. subtilis ATCase shares 56%
sequence identity with saATCase, the unliganded B. subtilis structure (PDB: 3R7D) [26]
was used to study conformational changes in saATCase upon ligand binding. The volume
of the unliganded B. subtilis active site pocket is 570 Å3, which is reduced significantly
upon PALA binding, to 64 Å3 in saATCAse as well as in B. subtilis (PDB: 3R7L) [26] and
Human ATCase (PDB: 5G1N) [139]. PALA has numerous interactions in the active site
of ATCase (Fig. 23B-D), like those described in ecATCase [140], explaining the
nanomolar affinity of this bisubstrate analog. The phosphonate group of PALA interacts
with the CP domain, especially with the side chains of Ser 48 and Arg 100 as well as Ser
75 and Lys 78 from the adjacent subunit. The α- and β-carboxylates of PALA interact with
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the side chains of Arg 160, Arg 210, and Gln 212 from the Asp domain. The amine group
of PALA interacts with the backbone carbonyl of Ala 253 to possibly increase the
nucleophilicity of the amino group of Asp when in close proximity to CP. Moreover, binding
of PALA induces significant conformational changes around the active site of ATCase.
When compared to B. subtilis unliganded ATCase, saATCase-PALA has considerable
conformational changes rearranging the 40’s loop (43-50), 70’s loop (66-82), 100’s loop
(100-105), and 120’s loop (122-126) in the CP domain and 160’s loop (158-168), 180’s
loop (183-192), and 220’s loop (211-225) in the Asp domain, essentially bringing them
closer to the active site (Fig. 23E). The most crucial conformation changes involve the
displacement of 70’s loop by 1.4 Å and 220’s loop by 12.6 Å resulting in substantial
closure of the hinge between CP and Asp domains by 10.6° (Fig. 23F). Superimposition
of B. subtilis unliganded ATCase and saATCase-PALA gave an RMSD of 1.82 Å for 288
Cα atoms (Fig. 23G).
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Figure 23: S. aureus ATCase Crystal Structure
A) Ribbon representation of the ATCase-PALA trimer in the asymmetric unit. Each chain
is shown in a different color. PALA is shown in yellow. B) 2mFo-DFc electron density map
(contour level 1σ) within 4.5 Å of PALA atoms. C) Interactions of PALA in the active site.
70’s loop of adjacent chain is shown in orange. D) Ligand interaction map for PALA in the
active site. E) Superimposition of unliganded B. subtilis (green) and saATCase-PALA
(red). F) Loop displacement and domain closure of saATCase-PALA (red) compared to
unliganded B. subtilis (green). G) RMSD plot depicting differences in Cα positions of 288
residues between B. subtilis unliganded ATCase and saATCase-PALA.
4.4.7 Effect of TEW on S. aureus ATCase Activity
Due to the inhibitory effect of TEW on P. aeruginosa ATCase, S. aureus ATCase
assay was performed to assess the effect of TEW on S. aureus ATCase activity. TEW
inhibited S. aureus ATCase to a lesser extent than P. aeruginosa ATCase with an IC50
value of 148 μM (Fig. 24).

Figure 24: IC50 of TEW against S. aureus ATCase
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S. aureus ATCase assay was performed with 2.5 mM carbamoyl phosphate, 2 mM
aspartate, and increasing concentrations of TEW.
4.5 Conclusion
S. aureus ATCase is a 99 kDa trimer composed of three catalytic chains. S. aureus
ATCase functions independently of DHOase and no evidence of association was
observed by size-exclusion chromatography, chemical cross-linking, or enzymatic assay.
Unlike B. subtilis, S. aureus ATCase has been shown to be inhibited by ATP and
allosterically regulated. The X-ray structure of S. aureus ATCase shares 56% sequence
identity with B. subtilis ATCase and both ATCases have a very similar tertiary structure.
S. aureus ATCase undergoes a domain closure upon binding to PALA, a bisubstrate
analog, to complete the catalytic cycle. TEW, the polyoxometalate, that displaced PALA
from the active site of P. aeruginosa ATCase and inhibited its activity also has an
inhibitory effect on S. aureus ATCase.
4.6 Future Directions
At present, the only high-resolution structure for S. aureus ATCase has PALA
bound in the active site. To fully understand the conformational changes in S. aureus
ATCase upon PALA binding, we need to obtain high-quality diffracting crystals of
unliganded S. aureus ATCase. We are using the closed conformation structure of S.
aureus ATCase for virtual screening of potential inhibitors. The structure of unliganded S.
aureus ATCase will also aid in virtual screening of compounds.
Experiments to be performed:
•

Kinetic study to determine whether ATP is a competitive or non-competitive
inhibitor
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•

Determine which pyrimidine and purine tri-, di-, and mono-nucleotides inhibit the
enzyme

•

Crystallization of apo S. aureus ATCase

•

Co-crystallization of S. aureus ATCase with CP to determine intermediate
conformation changes prior to Asp binding

•

Co-crystallization of S. aureus ATCase with ATP to determine ATP binding site

•

Co-crystallization of S. aureus ATC with TEW
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Chapter 5: Staphylococcus aureus Aspartate Transcarbamoylase StructureBased Drug Design against Bacteremia and Sepsis
5.1 Bacteremia and Sepsis
Bacteremia is the presence of bacteria in the bloodstream and is associated with
increased morbidity and mortality worldwide. Bacteremia can result from a breach of
integrity of the skin, immune system, or from direct penetration in the bloodstream. It can
result from existing local infection, dental procedure, surgical treatment of the infected
wound, colonization of indwelling catheters or prosthetic joints, or from vigorous
toothbrushing [141, 142]. S. aureus is a major cause of bacteremia and is one of the most
frequently isolated pathogens in hospital-acquired and community-acquired bloodstream
infections. S. aureus bacteremia poses a greater burden on the healthcare system
compared with bacteremia caused by any other pathogen [143]. S. aureus bacteremia is
associated with a longer duration of hospital stay, higher treatment cost, and a higher
mortality rate [144]. Patients with advanced age, a compromised immune system,
comorbidities, and intravenous drug use are at a higher risk of S. aureus bacteremia [145].
Bacteremia may be transient and cleared by the host immune system with no major
adverse consequences, but it may also lead to sepsis and death. Sepsis is characterized
by dysregulated host response and systemic inflammation to infection resulting in organ
dysfunction [146]. Sepsis presents with fever, tachycardia, tachypnea with normal blood
pressure. As sepsis develops into septic shock, it presents with decreased alertness and
hypotension [147, 148]. Organ dysfunction is identified by the quick SOFA score
(sequential organ failure assessment score): respiratory rate ≥ 22/min, altered mentation,
and systolic blood pressure ≤ 100 mm Hg, where all three criteria must be present. The
mortality rate increases with multiple organ failure.
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5.2 Current Therapeutics for Sepsis and Septic Shock
Broad-spectrum gram-positive and gram-negative combinatorial antibiotics are
administered intravenously as soon as possible and then therapy is narrowed after
pathogen identification and sensitivities. The source of infection is controlled by removing
potentially infected indwelling devices, drainage of an abscess, and debridement of
infected necrotic tissue. Furthermore, perfusion is restored with IV fluids and
vasopressors, and oxygen support is provided through mechanical ventilation [147, 149,
150].
5.3 Aspartate Transcarbamoylase as a Potential Therapeutic Target
Efficient utilization of available nutrients is a key for survival and pathogenesis of
bacteria in a host environment. Although host environments are nutrient rich, many
nutrients essential to bacterial growth are sequestered by the host, a term called
nutritional immunity [151]. Studies by Simmonds and Harkness [152] determined the
approximate level of uridine in human plasma to be 3 μmol/L. The bacteria can salvage
low levels of pyrimidines but eventually the bacteria must overcome the pyrimidine-limited
environment by upregulating the de novo pyrimidine biosynthesis pathway. A study by
Samant et al. [153], showed that the de novo nucleotide biosynthesis is very critical for
bacterial growth in human serum. This study demonstrated that inactivation of purine or
pyrimidine biosynthetic genes in E. coli, Salmonella enterica, or B. anthracis led to severe
growth defects of the mutants compared to the wildtype. Another study by Connolly et al.
[154], demonstrated that a defect in tetrahydrofolate synthesis led to significant growth
inhibition of S. aureus on human blood agar. This growth inhibition could only be rescued
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by the addition of thymidine suggesting that thymidine content in blood is not enough for
salvage and that pyrimidines are critical in bacterial survival.
ATCase catalyzes the committed step in the de novo pyrimidine biosynthesis
pathway in bacteria, is allosterically regulated by nucleotide triphosphates, and therefore
is an attractive drug target in pyrimidine biosynthesis. The active site of ATCase
composed of residues from adjacent monomers in a trimer is highly conserved in all
organisms. Therefore, our interest lies in the recognition and development of allosteric
inhibitors that bind away from the active site and inhibit ATCase activity.
5.4

Virtual

Screening

of

Compounds

against

S.

aureus

Aspartate

Transcarbamoylase
5.4.1 Test: Docking of PALA into the Active Site of S. aureus ATCase
The S. aureus ATCase-PALA structure was loaded into MOE [118] without PALA
bound in the active site. To fix structural issues, the protein was prepared using the
QuickPrep function. QuickPrep is an automated process for the correction, protonation,
and minimization of the structure. QuickPrep prepares structures by recognizing residues
with atoms having fractional occupancies and using the highest occupancy alternate by
default and by adding chemically appropriate hydrogen atoms. QuickPrep uses
Protonate3D for protonation and optimization of the orientation of the hydrogen atoms,
deletes water molecules farther than 4.5 Å from the protein, tethers atoms so the atoms
do not deviate too far from their initial positions, and energy minimizes the structure to an
RMS (Root Mean Square) gradient of 0.1 kcal/mol/A using Amber10:EHT forcefield
unless specified otherwise. PALA, saved as .mol2, was loaded into MOE, and the
molecule was washed. The Molecule Wash panel in MOE corrects for connected
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components to molecule and protonation states and scales bond lengths to 1.5 Å for
distorted structures. For PALA, the dominant protonation state at pH 7.0 was applied.
PALA was successfully docked in the active site of S. aureus ATCase using the default
settings in the General Dock panel. The placement was carried out using Triangle
Matcher and scored using London dG. Triangle Matcher generates poses by aligning
ligand triplets of atoms on triplets of alpha spheres [118]. The refinement was carried out
using Rigid Receptor and scored using GBVI/WSA dG. Rigid receptor option keeps
backbone and sidechain atoms of the receptor fixed.
5.4.2 Docking of FDA-Approved Compounds
Potential binding sites in S. aureus ATCase were identified using the Site Finder
[118] application in MOE. Site Finder identifies regions of tight atomic packing and
calculates alpha spheres on these regions. Alpha spheres are calculated by triangulation
of three-dimensional points and assigning a sphere for each resulting simplex or a
collection of four points. These alpha spheres are clustered to produce a collection of
sites. It then ranks the sites according to propensity for ligand binding (PLB) score based
on the amino acid composition in the site. When Site Finder was run on S. aureus
ATCase, the two sites chosen for virtual screening were at the trimer interface and the
interdomain cleft. The trimer interface was the highest-ranked site with a PLB score of
3.41, whereas the interdomain cleft had a PLB score of -0.18. The rationale for targeting
the trimer interface was that the small molecule would disrupt trimer formation which
would then lead to inhibition of ATCase activity, whereas targeting the cleft would interfere
with the domain closure that is essential to the catalytic cycle of ATCase.
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The FDA-approved compound library was obtained from the Zinc database [155].
The compounds were washed and the dominant protonation state at pH 7.0 was applied.
The compounds were docked at the trimer interface or at the interdomain cleft using the
default settings as described previously for PALA docking. The compounds with an S
score of -8 kcal/mol or lower were considered for further analysis.
5.4.3 Assessment of Top-Ranking FDA-Approved Compounds
The top three compounds with the lowest S score from docking of FDA-approved
compounds at the interdomain cleft compounds were pentoxifylline, ropinirole HCl, and
nitazoxanide. The binding poses of all the three compounds are shown in Fig. 25.
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Figure 25: Binding Poses of Top-Ranking FDA-Approved Compounds in the
Interdomain Cleft of S. aureus ATCase
The binding poses from docking of A) pentoxifylline, B) ropinirole HCl, and C)
nitazoxanide. The color scheme for the molecular surface is as follows: purple for
hydrogen bonding, green for hydrophobic, and blue for mildly polar.
The interdomain cleft is comprised of chain A Glu 46, Asn 47, Arg 160, Glu 214,
Arg 215 and chain C Ser 77 and Lys 78. All the residues except for Glu 46 are also a part
of the active site. Since the active site is conserved in all ATCases, the FDA-approved
compounds were docked in the active site of human ATCase (PDB: 5G1N) [139] and
were compared against S. aureus ATCase interdomain cleft.
Pentoxifylline is the top scoring compound with a docking score of -8.99 kcal/mol.
Pentoxifylline interacts with the S. aureus cleft residues Arg 100, Lys 78, and Arg 160
through hydrogen bonding and Arg 210 and Lys 78 through pi-cation interaction (Fig.
26A). Arg 100 in S. aureus cleft is corresponding to Arg 2085 in the human active site of
ATCase, and this Arg 2085 in human active site also interacts with pentoxifylline through
hydrogen bonding as in S. aureus cleft (Fig. 26B).
Ropinirole HCl has a docking score of -8.56 kcal/mol in the S. aureus cleft and has
a few interactions with the receptor. Ropinirole interacts with Ser 159, Val 161, and Ala
253 through hydrogen bonding and with Arg 210 though pi-cation interaction (Fig. 26C).
In human active site, ropinirole binding is much weaker with a docking score of -5.6
kcal/ml and it has only one hydrogen bond with the receptor (Fig. 26D).
Nitazoxanide has a docking score of -8.54 kcal/mol in the S. aureus cleft as
compared to -5.99 kcal/mol in the human active site of ATCase. It has several hydrogen
bond interactions with Ser 75, Arg 210, Gln 212, Arg 160, Thr 51, Arg 100, and Thr 49 in
the S. aureus cleft (Fig. 26E). None of these residues correspond to the residues in
human active site interacting with nitazoxanide (Fig. 26F).
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Figure 26: Ligand Interaction Maps
The top-ranking FDA-approved compounds were docked in the interdomain cleft of S.
aureus and the active site of human ATCase and the ligand interactions were compared,
pentoxifylline in A) S. aureus interdomain cleft, B) active site of human ATCase;
Ropinirole HCl in C) S. aureus interdomain cleft, D) active site of human ATCase;
nitazoxanide in E) S. aureus interdomain cleft, and F) active site of human ATCase
ATCase assays were performed to assess the effect of these compounds on S.
aureus ATCase activity. Pentoxifylline gave a 14% decrease in ATCase activity but the
inhibition was not dose-dependent. Nitazoxanide did not show any inhibition. Ropinirole
HCl gave an IC50 of 3.12 mM, however, it is not accurate as 3.12 mM is the highest
concentration used in the assay (Fig. 27).
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Figure 27: IC50 of Ropinirole HCl against S. aureus ATCase
S. aureus ATCase assay was performed with 2.5 mM carbamoyl phosphate, 2 mM
aspartate, and increasing concentrations of ropinirole HCl.
Most compounds with an S score of -8 kcal/mol or less from the trimer interface
were highly solvent exposed. Only one compound, indocyanine green, was considered
to study its effect on S. aureus ATCase activity. When assessed for ATCase activity, the
tubes containing indocyanine green turned deep yellow during the intermediate steps of
the assay, and it could not be analyzed further due to intrinsic interference of the
compound with the final step of the assay.
Furthermore, S. aureus ATCase was subjected to thermal shift assay in the
absence and presence of the top-scoring compounds to determine if any of the
compounds bind to the protein. The final concentrations of ATCase and the SYPRO
Orange were optimized to 0.1 mg/mL and 20X, respectively. Three concentrations of
pentoxifylline, ropinirole HCl, nitazoxanide, and indocyanine green, were tested: 1 mM,
0.1 mM, and 0.01 mM. Of all four compounds tested, only nitazoxanide showed a shift in
the melting temperature of S. aureus ATCase. Nitazoxanide led to a dose-dependent
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negative shift in the melting temperature of ATCase, with 1 °C shift at 0.01 mM, 2 °C shift
at 0.1 mM, and 5 °C shift at 1 mM (Fig. 28).

Figure 28: Effect of Nitazoxanide on the Thermal Stability of S. aureus ATCase
The thermal stability of S. aureus ATCase was measured nitazoxanide. The melting
temperature of ATCase is 54 °C in the absence of nitazoxanide (green), 53 °C with 0.01
mM nitazoxanide (pink), 52 °C with 0.1 mM nitazoxanide (purple), and 49 °C with 1 mM
nitazoxanide (blue).
5.5 Conclusion
Although the S. aureus interdomain cleft overlaps with the active site, the topranking FDA-approved compounds have differential docking in the S. aureus cleft
compared to the active site of human ATCase. None of the top-scoring compounds had
substantial inhibitory activity against S. aureus ATCase in vitro. Of all the compounds
tested, only nitazoxanide had a dose-dependent effect on the melting temperature of S.
aureus ATCase suggesting that although it binds S. aureus ATCase in vitro, the binding
is probably too weak to see its inhibitory effect at the concentrations tested.
5.6 Future Directions
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We have screened a very small subset from the extraordinarily large database of
compounds available. To discover promising inhibitors, we will have to screen many more
compounds. In terms of the few FDA-approved compounds explored in the lab, the
MedChem Transformations [118] operation was applied to discover novel chemical
structures from nitazoxanide because only nitazoxanide showed binding in thermal shift
analysis. MedChem Transformations applies various transformation rules to exchange
functional groups or alter the ring while preserving the rest of the ligand. The two chemical
structures as a result of transformation on nitazoxanide are shown in Fig. 29. It would be
worthwhile to determine how these newly transformed compounds dock in the cleft
compared to the parent compound, nitazoxanide, and how these compounds behave in
assay against ATCase activity. It would also be worthwhile to co-crystallize ropinirole HCl
with S. aureus ATCase due to its negligible effect on ATCase activity. If ropinirole HCl
binds in the cleft as predicted by the docking program, this compound can then also be
used as a starting point in designing more potent inhibitors.
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Figure 29: MedChem Transformations on Nitazoxanide
Compounds generated by MedChem transformation operation in MOE, A) nitazoxanide,
B and C) Novel structures generated by MedChem transformations on nitazoxanide.
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ABSTRACT
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Sepsis affects 1.7 million people in the United States every year and nearly
270,000 people die as a result. Sepsis is characterized by systemic inflammation from an
infection leading to organ dysfunction and death. Multi-drug resistance in bacteria is
increasing globally, and Pseudomonas aeruginosa and Staphylococcus aureus are
notorious for their multi-drug resistance and pose a serious need for the development of
new antibiotics. The levels of pyrimidines in blood are too low to sustain the growth of
bacteria, so they must rely on pyrimidine biosynthesis. Previous studies have shown that
a defect in several pyrimidine biosynthetic enzymes resulted in 1000-fold decrease in the
titer of bacteria growing in blood. Aspartate transcarbamoylase (ATCase) catalyzes the
first committed step of the de novo pyrimidine pathway, making it an attractive drug target
in pyrimidine biosynthesis. The following dissertation utilizes biochemical and biophysical
tools to understand the regulatory and structural properties of ATCase in P. aeruginosa
and S. aureus as well as to identify potential sites for ATCase inhibition.
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In this dissertation, I demonstrate that pDHO is a requirement for P. aeruginosa
ATCase because ATCase does not self-associate to form a stable trimer and that pDHO
facilitates ATCase trimer formation. The basis for why pDHO was a requirement for
ATCase activity was not explored previously. Additionally, I explore the role of N- and Cterminal extensions of P. aeruginosa ATCase and demonstrate that these extensions are
not involved in the ATCase-pDHO complex formation or nucleotide inhibition by ATP. This
led me to conclude that the binding site of ATP is not located in the 11-residue extension
of ATCase as previously suggested. Furthermore, I demonstrate that ATP inhibition of
ATCase is not an allosteric mechanism, rather it is a consequence of the destabilization
of the ATCase-pDHO complex. Lastly, I solved the crystal structure of P. aeruginosa delN
ATCase-pDHO complex with a molecule of TEW bound in the active site of delN ATCase
and demonstrated that TEW is a potent inhibitor of P. aeruginosa ATCase.
In my dissertation, I demonstrate that S. aureus ATCase is a stable catalytic trimer.
S. aureus ATCase functions independently and does not associate with DHOase. I solved
the crystal structure of S. aureus ATCase bound to an active site inhibitor, Nphosphonacetyl-L-aspartate (PALA), and validated that S. aureus ATCase undergoes
domain closure upon PALA binding as observed in other ATCases. Using this crystal
structure of S. aureus ATCase, I identified two sites for inhibition, including the
interdomain cleft and the trimer interface. I screened top-ranking FDA-approved
compounds against S. aureus ATCase in an in vitro assay after virtual screening.
Although none of the compounds had a significant inhibitory effect on S. aureus ATCase,
nitazoxanide showed dose-dependent destabilization of ATCase. This suggests that
nitazoxanide does not show inhibitory activity probably due to its poor binding to ATCase.
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